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Palavras-chave 
 
Hipertensão arterial pulmonar, disfunção ventricular direita, urocortina-2, 
recetor tipo 2 para a hormona libertadora de corticotropina. 
 
Resumo 
 
 
A hipertensão arterial pulmonar (HAP) é uma síndrome caracterizada por um 
aumento progressivo das resistências vasculares pulmonares e sobrecarga 
sobre o ventrículo direito que potencialmente levam à insuficiência cardíaca 
(IC) direita e consequentemente à morte. A urocortina (UCN)-2 é um péptido 
altamente expresso a nível cardiovascular que tem exibido efeitos terapêuticos 
benéficos tanto em humanos como em modelos animais de IC. Este estudo 
tem como principal objetivo explorar os efeitos da UCN-2 num modelo animal 
de IC ventricular direita (VD), secundário à HAP, e o seu impacto na função 
miocárdica. 
Ratos Wistar machos receberam aleatoriamente uma injeção de monocrotalina 
(MCT) ou veículo. Após 14 dias, os animais foram novamente sorteados para 
receber tratamento com UCN-2 ou veículo. Do estudo resultaram 4 grupos 
experimentais: CTRL, CTRL+UCN-2, MCT e MCT+UCN-2. As avaliações 
ecocardiográficas, estudos hemodinâmicos e colheita de amostras para 
análise morfométrica, histológica e molecular foram realizados 24-25 dias após 
a administração de MCT. 
Os animais injetados com MCT desenvolveram HAP e IC VD, demonstrado 
pelo comprometimento do fluxo pulmonar, dilatação VD e aumento das 
pressões VD, assim como um débito cardíaco diminuído. A administração de 
MCT também levou à hipertrofia VD. O tratamento com UCN-2 conseguiu 
recuperar as alterações induzidas pela HAP na função e estrutura cardíacas. 
Ainda, os animais MCT+UCN-2 tiveram uma maior taxa de sobrevivência 
quando comparados com os MCT. Os estudos moleculares revelaram uma 
expressão genética e uma fosforilação proteica alterada nos animais MCT, de 
alguns componentes do sistema UCN-2/CRHR2. 
Em suma, com este estudo demonstramos que o tratamento crónico com 
UCN-2 é capaz de restaurar as alterações induzidas pela HAP na função e 
estrutura cardíacas, assim como reverter as alterações na expressão de 
marcadores cardíacos de sobrecarga, hipertrofia, hipóxia e apoptose induzidos 
pela doença. Estes resultados sugerem que a via UCN-2/CRHR2 tem um papel 
relevante na fisiopatologia da HAP e progressão para IC, representando um 
potencial alvo terapêutico. 
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Pulmonary arterial hypertension, right ventricular dysfunction, urocortin-2, 
corticotropin-releasing hormone receptor 2. 
 
Abstract 
 
Pulmonary arterial hypertension (PAH) is a syndrome based on diverse 
aetiologies, characterized by a persistent increase in pulmonary vascular 
resistance and overload of the right ventricle (RV), leading to heart failure (HF) 
and death. Urocortin (UCN)-2 is a peptide highly expressed in the 
cardiovascular system that has shown promising therapeutic effects in several 
studies both in humans and animal models of HF. Thus, this study aims to 
explore the effects of UCN-2 treatment in an animal model of RV HF secondary 
to PAH and its impact on myocardial function. 
Male Wistar rats (180-200g) randomly received monocrotaline (MCT, 60mg/kg) 
or vehicle. After 14 days, animals were randomly assigned to receive UCN-2 
treatment (5μg/kg/day) or vehicle. The study resulted in 4 groups: CTRL (n=9), 
CTRL+UCN-2 (n=9), MCT (n=7) and MCT+UCN-2 (n=10). Echocardiographic, 
hemodynamic studies and sample collection were performed 24-25 days after 
MCT administration. Only significant results (mean±SEM, p<0.05) are given. 
MCT animals developed PAH, demonstrated by impaired pulmonary flow, RV 
dilation and increased RV pressures, as well as decreased cardiac output. 
MCT administration also resulted in RV hypertrophy. UCN-2 treatment was 
able to restore PAH-induced severe abnormalities in cardiac function and 
structure. Moreover, Kaplan-Meier analysis showed increased survival rate for 
MCT+UCN-2 rats when compared with the MCT group. The molecular studies 
revealed an altered genetic expression of the UCN-2/CRHR2 system 
components in the MCT animals, as shown by the increase in molecular 
markers of hypertrophy, overload, hypoxia and apoptosis that were reversed 
with UCN-2 treatment. As well as an impaired protein 
activation/phosphorylation seen in peptides pertaining to different signaling 
pathways. 
In conclusion, we show that UCN-2 chronic treatment is able to restore PAH-
induced severe abnormalities in cardiac function and structure, as well as to 
reverse the changes in the expression of markers of cardiac overload, 
hypertrophy, hypoxia and apoptosis induced by the disease. The beneficial 
effects of UCN-2 seem to be associated with the modulation of numerous 
signaling pathways, such as survival and proliferation. These findings suggest 
that the UCN-2/CRHR2 pathway has a relevant role on the pathophysiology of 
PAH and progression to RV failure, representing a potential therapeutic target. 
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Cyclic adenosine monophosphate 
 
CCB 
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Endothelial nitric oxide synthase 
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Exchange protein activated by cAMP 
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Pulmonary arterial endothelial cell 
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2+
-ATPase 
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STAT3 
Signal transducer and activator of transcription 3 
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Overview of Pulmonary Arterial Hypertension 
The term Pulmonary Hypertension (PH) encircles several disorders mainly characterized 
by the presence of abnormally high pulmonary vascular pressure. Pulmonary arterial 
hypertension (PAH), the largest group of PH, is a syndrome based on diverse aetiologies that 
results from restricted blood flow through the pulmonary arterial circulation resulting in 
increased pulmonary vascular resistance (PVR) and overload of the right ventricle (RV), leading 
to heart failure (HF) and death1. 
 
Definition 
PAH is defined by a mean pulmonary artery pressure (mPAP) equal to or greater than 
25mmHg at rest, and is hemodynamically characterized (Table 1) by the presence of pre-
capillary PH, which implies a normal pulmonary capillary wedge pressure (PCWP) or left 
ventricular end-diastolic pressure (LVEDP) of 15mmHg or less with a PVR greater than 3 Wood 
Units (mmHg/l•min)1, 2. So far there is no sufficient evidence to add an exercise criterion to this 
definition3. 
 
TABLE 1. Hemodynamic definitions of Pulmonary Hypertension* 
Definition Characteristics Clinical Group(s) 
PH mPAP ≥ 25mmHg All 
Pre-capillary PH 
mPAP ≥ 25mmHg 
PWP ≤ 15mmHg 
CO normal or reduced
#
 
1. PAH 
3. PH due to lung diseases 
4. Chronic thromboembolic PH 
5. PH with unclear and/or 
multifactorial mechanisms 
 
Post-capillary PH 
 
Passive 
Reactive (out of proportion) 
mPAP ≥ 25mmHg 
PWP > 15mmHg 
CO normal or reduced
#
 
TPG ≤ 12mmHg 
TPG > 12mmHg 
2. PH due to left heart disease 
*All values measured at rest. #High CO can be present in cases of hyperkinetic conditions such as systemic-to-pulmonary shunts 
(only in the pulmonary circulation), anaemia, hyperthyroidism, etc. Abbreviations: CO, cardiac output; mPAP, mean pulmonary 
arterial pressure; PH, pulmonary hypertension; PWP, pulmonary wedge pressure; TPG, transpulmonary pressure gradient (mean 
PAP-mean PWP). Adapted from Galiè et al. (3). 
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Clinical Classification 
Since the first World Symposia on Pulmonary Hypertension (WSPH) in 1973 held in 
Geneva, Switzerland, the clinical classification of PH has gone through a series of alterations. 
Initially, a simple classification divided only in two categories was proposed: primary and 
secondary PH, depending on the presence or absence of identifiable causes or risk factors4, 5. In 
the following WSPHs, new classifications have been proposed based on emerged knowledge 
about PH pathophysiology, clinical features and therapeutic options5, 6. 
The latest classification was established during the fifth WSPH in Nice, France, in 2013 
(Table 2)7 and individualizes five PH categories according to pathological findings, 
hemodynamic characteristics and similar therapy: PAH (Group 1); PH due to left heart diseases 
(Group 2); PH due to chronic lung disease and/or hypoxia (Group 3); chronic thromboembolic 
PH (CTEPH) (Group 4) and PH due to unclear multifactorial mechanisms (Group 5). 
In Group 1, idiopathic PAH corresponds to sporadic disease in which there is no familial 
history nor identified risk factors. When PAH occurs in a familial context, it is labeled heritable 
PAH and emerges from germline mutations mainly in the gene coding for the bone 
morphogenetic protein receptor type 2 (BMPR2) (>70% cases), a member of the transforming 
growth factor beta (TGF-β) signaling family. Mutations like this also have been found in 11-40% 
of idiopathic cases with no familial record8. Several drugs like aminorex, fenfluramine and 
dexfenfluramine (appetite suppressants), and/or toxic rapeseed oil represent a clear risk factor 
for PAH development, therefore it represents an isolated PAH category. The last PAH group 
encircles several diseases closely related to PAH, such as, connective tissue diseases, human 
immunodeficiency virus (HIV) infection, portal hypertension, congenital heart diseases (CHD) 
and schistosomiasis7, 9. 
 
TABLE 2. Updated clinical classification of Pulmonary Hypertension (Nice, 2013) 
1. PAH 
1.1. Idiopathic PAH 
1.2. Heritable PAH 
1.2.1. BMPR2 
1.2.2. ALK1, ENG, SMAD9, CAV1, KCNK3 
1.2.3. Unknown 
1.3. Drugs and toxins induced 
1.4. Associated with (APAH) 
1.4.1. Connective tissue diseases 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseases 
1.4.5. Schistosomiasis 
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1’.    Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1’’.   Persistent PH of the newborn (PPHN) 
2. PH due to left heart disease 
2.1. Left ventricular systolic dysfunction 
2.2. Left ventricular diastolic dysfunction 
2.3. Valvular disease 
2.4. Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
3. PH due to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental lung diseases 
4. Chronic thromboembolic PH (CTEPH) 
5. PH with unclear multifactorial mechanisms 
5.1. Hematological disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, 
neurofibromatosis, vasculitis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH 
Abbreviations: ALK1, activin receptor-like kinase-1 gene; BMPR2, bone morphogenetic protein receptor type II; CAV1, caveolin-1; 
ENG, endoglin; HIV, human immunodeficiency virus; KCNK3, potassium channel subfamily K member 3; PH, pulmonary 
hypertension; PAH, pulmonary arterial hypertension; SMAD9, mothers against decapentaplegic homolog 9. Adapted from 
Simonneau et al. (7). 
 
Pathophysiology 
HISTOPATHOLOGY 
PAH is considered a vasculopathy, and in general, all PAH subgroups (Group 1) and other 
forms of PH (i.e. PH owing to lung disease and/or hypoxia) exhibit several arterial 
abnormalities mainly present in small pulmonary arteries and arterioles1. The most common 
pathologic features in PH are medial hypertrophy, dilation and intimal atheromas and because 
they are present in all forms of PH, they hold poor diagnostic value. However, PAH is 
characterized by constrictive lesions, which include medial hypertrophy, and intimal and 
adventitial thickening, and by complex lesions that includes plexiform and dilation lesions, as 
well as arteritis10. 
Medial hypertrophy 
Is defined by an increase of the diameter of the medial layer, measured between the 
internal and the external elastic lamina, exceeding 10% of the arteries cross-sectional 
diameter. This abnormality appears in all PAH subgroups and occurs due to pulmonary arterial 
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smooth muscle cell (PASMC) proliferation and/or recruitment to the tunica media. This lesion 
is considered an early event in PAH pathogenesis but it is usually regarded as a reversible 
one10. 
Intimal and adventitial thickening 
This occurs due to the proliferation and recruitment of fibroblasts, myofibroblasts and 
other connective tissue cells, and consequently by the interstitial deposition of collagen, 
leading to fibrosis. This thickening can be uniform (concentric) or focal (eccentric) being the 
former often associated with thrombotic events11. 
Plexiform lesions 
This abnormality affects several vascular compartments and it’s very PAH-
characteristic11. The formation of these lesions occurs due to the local and excessive 
endothelial cell (EC) proliferation, which leads to the formation of capillary-like channels on a 
myofibroblasts, smooth muscle cells (SMC) and connective tissue-rich matrix within the arterial 
lumen12. These lesions are responsible for the expansion and partial destruction of the arterial 
wall, since they tend to enlarge into the perivascular connective tissue. Fibrin, thrombi and 
platelets are frequently encountered in these lesions10, 13. 
Dilation lesions and arteritis 
The first is usually located near a plexiform lesion and is a thin-walled vein-like vessel, 
representing a potential cause for hemorrhages and subsequent fibrosis. In arteritis, necrotic 
and fibrotic tissue may accumulate in the artery wall and/or infiltration with inflammatory 
cells10. 
 
CELLULAR FACTORS 
Several different cell populations are involved and contribute to these types of lesions14. 
The main mechanisms responsible for this pulmonary vascular dysfunction are the abnormal 
proliferation of SMC and EC, infiltration of inflammatory cells and fibrosis15. However, PAH 
cannot only be associated with cell proliferation but also with apoptotic processes, since it is 
supposed that an imbalance between these two events is the major responsible for the 
narrowing of pulmonary arteries in PAH16. 
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Smooth muscle cells and fibroblasts 
All forms of PAH have in common the migration and proliferation of SMC, which in 
general is accompanied by the migration of fibroblasts and formation of an extracellular matrix 
layer. This uncontrolled proliferation of SMCs ultimately leads to media hypertrophy, also 
contributing to the thickening of the intima and adventitia layers of the pulmonary vessels17. 
The formation of an extracellular matrix and myofibroblasts between the endothelium and 
internal elastic lamina is termed neointima. Another PAH characteristic feature is the increase 
in vasa vasorum neovascularization which mainly affects the adventitia, being able to expand 
to the media18. 
Endothelial cells 
In response to shear stress, hypoxia, inflammation and/or other stimuli, ECs proliferate 
beyond limit and generate plexiform lesions19. ECs in response to these stimuli may undergo 
through changes in proliferative and apoptotic processes, as well as changes at the functional 
level. Endothelial dysfunction eventually results in a clear imbalance between the production 
and release of vasoconstrictors/vasodilators, activator/inhibitory growth factors, 
prothrombotic/antithrombotic mediators and proinflammatory/anti-inflammatory signals20, 21. 
Inflammatory cells 
In certain forms of PAH (i.e. PAH associated with auto immune diseases) the 
inflammatory response plays an important role, since some patients improved both clinically 
and hemodynamically when administered immunosuppressant therapy. A fraction of patients 
(30-40%) have circulating auto-antibodies and elevated plasma levels of interleukin (IL)-1 and 
IL-6. Moreover, some inflammatory cells, such as lymphocytes and macrophages, can also be 
found in plexiform lesions20. 
Thrombosis and platelet dysfunction 
Some PAH patients exhibit elevated plasma levels of fibrinopeptides, along with von-
Willebrand factor and plasminogen activator inhibitor type 1, reflecting an abnormal 
coagulation process and endothelial dysfunction, respectively. Both events are very important 
in PAH development because they can generate or aggravate in situ thrombosis. Platelets also 
participate in vasoconstriction and vascular remodeling, since they are able to produce 
prothrombotic, vasoactive and mitogenic factors22. 
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MOLECULAR ABNORMALITIES 
The molecular abnormalities seen in PAH patients are normally associated with 
increased endothelin (ET)-1 levels and decreased nitric oxide (NO) and prostacyclin levels, 
since these factors influence vascular homeostasis, cell survival and proliferation, among other 
processes. 
Prostanoids 
Prostacyclin or prostaglandin I2 (PGI2) and thromboxane A2 (TXA2) belong to the 
prostanoids family and are produced from arachidonic acid metabolites. The former is a potent 
vasodilator and inhibitor of platelet activation and cellular proliferation, while TXA2 is a 
vasoconstrictor and promotes these cellular mechanisms1. PGI2 is produced in vascular ECs 
and acts on vascular smooth muscle cells (VSMC) as well as circulating platelets and cells, via 
the cyclic adenosine monophosphate (cAMP) pathway23. In PAH patients, the expression of 
PGI2 synthase in pulmonary arteries is reduced and therefore the production of prostacyclin in 
ECs is evidently decreased24. 
Endothelin-1 
This 21-amino acid vasoactive peptide is expressed in several mammalian tissues in 
different types of cells and is responsible for the regulation of vascular tone. ET-1 exerts its 
effects through the interaction with two types of receptors, endothelin receptor-type A (ETA) 
and –type B (ETB), which belong to the G-protein-coupled receptors (GPCRs) family and are in 
general highly homologous. In PASMCs, when activated, both receptors have a vasoconstrictor 
effect, while in pulmonary arterial endothelial cells (PAEC), ETA is not expressed and the 
activation of ETB leads to vasodilatation
25. EC dysfunction usually leads to ET-1 overexpression, 
which results in vasoconstriction and reduced synthesis of NO and prostacyclin, worsening the 
vasoconstrictor response. The upregulation of ET-1 is also involved in inflammatory responses 
and increased fibrosis15. In PAH patients, ET-1 levels are elevated and it’s clearance in the 
pulmonary vasculature is reduced. The plasma levels of this peptide can be correlated with the 
severity of PAH and its prognosis26, 27. 
Endothelial nitric oxide 
NO is a 30Da lipophilic gaseous molecule that can be synthesized in mammalian tissues 
via activation of either one of the three NO synthase (NOS) isoforms, which have the ability to 
catalyze the formation of NO from L-arginine in a two-step reaction. NO is a vasodilator that 
modulates several physiological processes, being also capable of inhibiting leukocyte adhesion, 
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platelet aggregation, thrombus formation, and vascular proliferation23. Endothelial NOS (eNOS) 
can be activated either by GPCR signal transduction, which increases intracellular Ca2+ levels 
and, subsequently, levels of Ca2+-calmodulin; Akt signaling; vascular endothelial growth factor 
(VEGF) and hormonal stimuli (e.g. estrogen and insulin)25. In both animal models of PH and 
humans with this syndrome, decreased pulmonary vascular eNOS activity is observed, along 
with loss of NO bioavailability, which is linked to impaired endothelium-dependent and -
independent vasodilatation, increased PASMC mitogenesis and platelet aggregation25, 28. 
Phosphodiesterase inhibition 
Phosphodiesterase (PDE) enzymatic activity is implicated in the endogenous degradation 
of cAMP29, and currently, eleven PDE isoforms are known in mammalian tissue30. More 
specifically, in the setting of PH, PDE type-5 has gaining some interest since it was identified in 
elevated concentrations in PASMCs, platelets and myocytes. PDE-5 regulates cyclic guanosine 
monophosphate (cGMP) bioactivity via hydrolysis of cGMP to 5’-GMP and allosteric binding of 
cGMP to PDE-5, which induces a conformational change to the structure of the latter, that 
positively feeds back to promote cGMP metabolism25. In a setting of PAH, expression of PDE-5 
is increased in both PASMCs and RV myocytes31,32 being associated with decreased levels of 
NO, pulmonary vascular dysfunction and impaired RV lusitropy33. In PASMCs in vitro, PDE-5 
inhibition reduces DNA synthesis/cell growth, cellular proliferation, and suppression of 
apoptosis32, being also linked to decreased thrombotic burden in CTEPH, presumably by 
increasing bioactive cGMP levels in platelets to inhibit platelet aggregation34. 
Potassium channels 
The inhibition of voltage dependant potassium channels in PASMC results in membrane 
depolarization and opening of voltage dependant calcium channels, which leads to an increase 
in [Ca2+]i and cellular contraction
11. This inhibition can result from a variety of stimuli, such 
hypoxia or anorexigens35. Some of these channels are downregulated in PAH patients36. 
Serotonin 
Serotonin (5-hydroxytryptamine, 5-HT) is a vasoconstrictor agent that is also capable of 
promoting PASMC hypertrophy and hyperplasia1. While 5-HT transporter (5-HTT) facilitates the 
induction of proliferation since it carries 5-HT into PASMCs, the 5-HT1B receptor mediates 
vasoconstriction, both contributing to PAH pathogenesis37. PAH patients usually present 
elevated plasmatic concentrations of 5-HT38. 
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Rho proteins 
Several cellular functions such as contraction, migration, proliferation and apoptosis are 
regulated by Rho proteins and especially Rho protein A and Rho kinases have been implicated 
in PAH vasoconstriction and vascular remodeling39. The signaling pathway involving these 
proteins is directly involved in 5-HTT-mediated PASMC proliferation and platelet activation 
during PH progression40. 
 
GENETIC MUTATIONS 
If not associated with other clinical condition or induced by toxins, PAH can be either 
idiopathic or heritable. This disease segregates an autosomal dominant trait with a markedly 
reduced penetrance, since only 10-20% of individuals that carry the mutation will develop 
PAH41. The BMPR2 is a serine/threonine receptor kinase that belongs to the family of TGF-β. In 
58-74% of PAH patients with familial history of the disease, and in 35-40% of idiopathic PAH 
patients, germline BMPR2 mutations can be detected42,43. Mutations in BMPR2 cause an 
aberrant signal transduction in PASMC, resulting in an imbalance between apoptosis and 
proliferation in favor of the latter44. Other two PAH predisposing genes are ALK1 that codes for 
Activin-Like Kinase type I receptor, present in ECs, and ENG (endoglin), and are most common 
in patients displaying hereditary hemorrhagic telangiectasia45, 46. Most recently, a few studies 
described mutations in more than one SMAD genes47. Interestingly, all genes mentioned above 
encode proteins involved in the TGF-β signaling pathway, which may be a trigger for 
pulmonary vascular remodeling since this signaling pathway controls growth, differentiation 
and apoptosis in different cell types48. 
 
The Right Ventricle 
Though the development of right heart (RH) failure is secondary to pulmonary vascular 
remodeling in PAH, the former is the immediate cause of death in most patients. Therefore, 
the integrity of RV function, rather than the degree of vascular injury, is the major determinant 
of prognosis in PAH49. The abnormal changes that occur in the pulmonary arteries of PAH 
patients, at first leads to vessel narrowing and/or obstruction, which then results in a 
progressive increase in PVR and mPAP50. 
In a normal heart, the RV, which differs anatomically from the left ventricle (LV), is able 
to adapt and respond to an increase in load with an increase in contractility since its thin wall, 
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crescent shape and greater compliance give the RV the ability to adapt rapidly to changes in 
volume and pressure load49. 
In PAH patients, initially the RV copes with increased afterload, with an enhanced 
contraction and a concentric RV remodeling, while the right atrium pressure remains normal. 
The rise in ventricular pressures increases diastolic and systolic stretch on the RV wall, which 
firstly leads to an increase in muscle mass – adaptive hypertrophy – due to increased protein 
synthesis and cardiomyocyte size. However, if the pressure overload is maintained, the RV 
cannot sustain the adaptive hypertrophy and eventually dilates, without any increase in RV 
contractility, despite further increases in load, reaching a state called uncoupling of the RV51. 
The mechanisms involved in further adaptation of the RV and decline of its contractility 
are poorly understood, but it is thought to be associated with an imbalance between oxygen 
supply and demand52, increased chronic sympathetic activation53, oxidative and nitrosative 
stress, immune activation and cardiomyocyte apoptosis51. 
The increase in ventricular volume may also lead to tricuspid regurgitation, which results 
in RV volume overload and thus further RV decline. The latter is accompanied by an increase in 
RV contraction time and ventricular asynchrony together with a decrease in RV stroke volume 
(SV), leading to underfilling of the LV54. The impaired LV filling in concert with RV dysfunction 
contributes to the evident decline in cardiac output (CO) seen in severe cases of PAH, and if 
not interrupted, these circle of events end in RH failure and eventually death50. 
 
Epidemiology and Survival 
PAH is a rare and seriously underdiagnosed syndrome, with an estimated prevalence of 
15-50 cases per million people and an incidence of 2.4 cases per million people per year, 
however the prevalence in certain at-risk groups is substantially higher55. For instance, 
according to the French registry, in the associated PAH subgroup, 15.3% PAH patients had 
connective tissue diseases, 11.3% had congenital heart diseases, 10.4% had portal 
hypertension, 9.5% had anorexigen-associated PAH and 6.2% had HIV infection43. Idiopathic 
PAH is 2-4 times more common in women than in men and accounts for at least 40% of PAH 
cases, with associated PAH accounting for the majority of the remaining cases55. 
The published data regarding Portugal is scarce, but according to the recent Portuguese 
nationwide registry, in a cohort of 79 patients, 58.2% were classified as having PAH. This study 
showed a clear preponderance of women among PAH patients, with a female/male ratio of 
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1.9:1. The majority of patients were between 21 to 60 years of age. Idiopathic PAH was 
present in 37% of the patients, followed by connective tissue disease (26%), congenital heart 
disease (22%), portopulmonary hypertension (11%), familial (2%) and other etiologies (2%)56. 
In treated PAH patients, the survival rates improved to 96% after 1 year and 89% after 2 
years57. While the untreated patients, face an estimated mean survival of 2.8 years, with 1-, 3- 
and 5-years survival rate of 68%, 48% and 34%, respectively58.  
 
Symptoms 
Due to the non-specific nature of the symptoms, PAH is frequently diagnosed when 
patients have reached an advanced stage of disease43. The most common early symptoms 
include breathlessness, fatigue, weakness, angina, syncope and abdominal distension. 
Regarding physical signs, normally there is a left parasternal lift, an accentuated pulmonary 
component of the second heart sound, a systolic murmur of tricuspid regurgitation, a diastolic 
murmur of pulmonary insufficiency and a RV third sound. In a more advanced stage, patients 
often show a jugular vein distension, hepatomegaly, peripheral edema, ascites and cold 
extremities3. 
 
Diagnosis 
The evaluation of a patient with suspected PH requires a series of tests and exams 
intended to confirm the diagnosis, clarify the clinical group of PH and the specific etiology 
within the PAH group, being also important to evaluate the functional and hemodynamic 
impairment present3. 
Initially, patients with suspected PAH undergo a transthoracic echocardiography, which 
is an ultrasound-based technique that provides several variables that can be correlated with 
RH hemodynamic parameters59 and it is normally performed in cases of suspected PH, as a first 
approach. In order to confirm the diagnosis of PAH, a RH catheterization (RHC) is necessary 
and also useful to assess the severity of hemodynamic impairment and to test the 
vasoreactivity of the pulmonary circulation60. Patients with idiopathic PAH, who might benefit 
from long-term calcium-channel blocker (CCB) therapy are normally subjected to this acute 
vasodilator test, which is performed at the time of RHC through the administration of 
pharmacologic agents61. Patients with evident RH failure or hemodynamic instability are 
excluded from the test3. 
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In patients of suspected PAH, evaluation of other potential etiologies, such as 
thromboembolic disease, is recommended, in order to redirect the therapy to the source of 
the problem3. 
 
Prognosis 
Both clinical and hemodynamic assessments derive from patients cohort’s data and 
therefore may not accurately reflect the prognosis of individuals with the disease. However, 
they yield important predictive information which may guide clinical management. Despite 
large inter-observer variation in the measurement, WHO functional class (WHO-FC), depicted 
in Table 3, remains a powerful predictor of survival.  
 
TABLE 3. Functional classification of PH modified after the New York Heart Association      functional 
classification according to the WHO 1998. 
Class I 
Patients with PH but without resulting limitation of physical activity. Ordinary physical activity 
does not cause undue dyspnoea or fatigue, chest pain, or near syncope. 
Class II 
Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity causes undue dyspnoea or fatigue, chest pain, or near syncope. 
Class II 
Patients with PH resulting in marked limitation of physical activity. They are comfortable at 
rest. Less than ordinary activity causes undue dyspnoea or fatigue, chest pain, or near 
syncope. 
Class IV 
Patients with PH with inability to carry out any physical activity without symptoms. These 
patients manifest signs of RH failure. Dyspnoea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity. 
Abbreviations: RH, right heart; PH, pulmonary hypertension. Adapted from Galiè et al. (3). 
 
Echocardiographic evaluation remains a good tool to access cardiac structure and 
function since it is non-invasive and generates many indices, such as pericardial effusion, right 
atrial area (RAA), RV and pulmonary artery dimensions62 and RV Doppler index63, which carry a 
high prognostic value. Also, tricuspid annular plane systolic excursion (TAPSE) has been 
reported to be of prognostic value64. Amongst the hemodynamic measurements, mPAP has 
some prognostic value, but it is less reliable as it may fall towards the end stage of the disease 
as the RV fails. Some studies suggest that reduced arterial O2 saturation, low systolic blood 
pressure, and increased heart rate (HR) carry a worse prognosis65. 
For the assessment of exercise capacity of patients with PAH the 6-minute walk test 
(6MWT) and the cardiopulmonary exercise testing (CPET) are used. The former is technically 
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simple, inexpensive, reproducible and well standardized, and in addition to distance walked, 
dyspnoea on exertion (Borg scale) and finger O2 saturation are also recorded. However, this 
test is not sufficiently validated in PAH subgroups and it can be influenced by body weight 
(BW), gender, height, age and patient motivation66. In CPET, gas exchange and ventilation are 
continuously recorded during incremental exercise. In PAH patients, O2 uptake at the 
anaerobic threshold and peak exercise are reduced in relation to disease severity, as well as 
the peak work rate, peak heart rate, O2 pulse and ventilatory efficiency
67. 
Recently some biomarkers have emerged as an attractive non-invasive tool to monitor 
RV dysfunction in patients with PAH and to evaluate the prognosis severity. For instance, brain 
natriuretic peptide (BNP) induces vasodilatation and natriuresis as it is released from the 
myocardium in response to wall stress. The biologically inactive N-terminal segment (NT-
proBNP), derived from the cleavage of a higher molecular weight precursor of BNP (proBNP), 
has an extensive half-life and is very stable even after sampling, providing a useful quantifiable 
marker. The baseline median value of BNP which distinguishes a good from a bad prognosis is 
150pg/mL68. Low or decreasing BNP/NT-proBNP levels may be a useful marker of successful 
disease control in PAH. Increased levels of Troponin T and Troponin I in plasma represents a 
marker of myocardial damage and are useful prognostic indicators in acute coronary 
syndromes and acute pulmonary embolism. However, the monitoring value of the cardiac 
Troponin T levels in plasma still requires confirmation since in some patients they disappear 
temporarily or permanently after treatment initiation69. Currently there are other circulating 
biomarkers under investigation70, 71, still waiting for clinical validation. 
Patients who experience falling exercise capacity, syncope, hemoptysis and have signs of 
RV failure carry a poor prognosis. If untreated, PAH patients show a median survival of 6 
months for WHO-FC IV, 2.5 years for WHO-FC III, and 6 years for WHO-FC I and II3 (Table 4). 
 
TABLE 4. Determinants of Pulmonary Arterial Hypertension* prognosis 
Determinants of Risk Lower Risk (Good Prognosis) Higher Risk (Poor Prognosis) 
Clinical evidence of RV failure No Yes 
Progression of symptoms Gradual Rapid 
WHO class
‡
 II, III IV 
6MW distance
§
 Longer (>400 m) Shorter (<300 m) 
CPET Peak VO2 >10.4 mL/kg/min Peak VO2 <10.4 mL/kg/min 
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Echocardiography Minimal RV dysfunction 
Pericardial effusion, significant RV 
enlargement/dysfunction, RA 
enlargement 
Hemodynamics RAP <10 mmHg, CI >2.5 L/min/m
2
 RAP >20 mmHg, CI <2.0 L/min/m
2
 
BNP
#
 Minimally elevated Significantly elevated 
*Most data available pertains to idiopathic PAH. One should not rely on any single factor to make risk predictions. ‡The WHO class 
is the functional classification for PAH and is a modification of the New York Heart Association functional class. §6MW distance is 
also influenced by age, gender, and height. #As there is currently limited data regarding the influence of BNP on prognosis, and 
many factors including renal function, weight, age and gender may influence BNP, absolute members are not given for this 
variable. Abbreviations: 6MW, 6-minute walk; BNP, brain natriuretic peptide; CI, cardiac index; CPET, cardiopulmonary exercise 
testing; peak VO2, average peak oxygen uptake during exercise; RA, right atria; RAP, right atrial pressure; RV, right ventricle; WHO, 
World Health Organization. Adapted from Mclaughlin et al. (1). 
 
Therapy 
Currently the pathogenesis of PAH is poorly understood and although the existing 
treatments can improve clinical symptoms, they cannot cure PAH. 
 
GENERAL MEASURES 
Physical activity adapted to patient’s symptoms is recommended and though there is no 
evidence of cardiac hemodynamic improvement, 6MWD and quality of life seem enhanced. 
Oxygen therapy may also be an option, especially in patients with chronic obstructive 
pulmonary disease while hypoxic conditions should be avoided, such as high altitude travel. 
Pulmonary infections should be prevented since they can deteriorate PH symptoms. Pregnancy 
should also be avoided since it contributes to 30-50% mortality in PAH patients23. 
In some cases, non-specific drugs such as diuretics and anticoagulants, can be 
administered, since they have the ability to decrease RV overload and in situ thrombosis, 
respectively, improving PAH symptoms23. 
Calcium channel blockers 
Because initially vasoconstriction was assumed to be a preponderant mechanism in PAH, 
CCBs were introduced as part of PAH therapy and in some cases they are able to induce a 
beneficial vasodilator response72,73. This therapy is only indicated in patients that showed a 
positive vasodilatation reaction after inhaled NO. In the absence of acute vasoreactivity, CCB 
therapy must be avoided, since it can dramatically reduce CO and systemic blood pressure. 
Moreover, CCB is not advised in pulmonary veno-occlusive disease because of the risk of 
pulmonary edema61. 
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SPECIFIC TREATMENT 
The growing knowledge about the interplay between signaling pathways in pulmonary 
arterial ECs and SMCs, lung fibroblasts, and RV myocytes that occur in response to injury has 
led to the development of PAH-specific pharmacotherapies23, already approved for the 
treatment of PAH. 
Prostanoids 
PGI2 or prostacyclin, is an arachidonic acid produced by ECs that induces relaxation in 
both systemic and pulmonary vascular smooth muscle and inhibits platelet aggregation 
through the increase in intracellular cAMP levels15. PGI2 also plays an important role in 
antiproliferative, antithrombotic, antimitogenic and immunomodulatory activity23. In fact, 
patients with PAH have reduced endogenous prostacyclin, which contributes to the 
pathogenesis of the disease24. 
Phosphodiesterase type-5 inhibitors 
The vasodilator activity of NO in VSMC is achieved through the up-regulation of cGMP, 
whose metabolism depends on the activation of PDEs, since the latter is responsible for the 
hydrolytic breakdown of cGMP. Three types of PDEs enzymes can be found in pulmonary 
arterial contractive cells, but PDE-5 is the most expressed isoform in pulmonary circulation23. 
Endothelin receptor antagonists 
ET-1 is a potent vasoconstrictor and a SMC mitogen that contributes to the development 
of PAH. Elevated ET-1 levels are frequently correlated with poor prognosis in PAH patients. 
Endothelin receptor antagonists (ERAs) act by blocking the binding of ET-1 to its receptors, 
inhibiting its downstream effects. So far, several types of ERAs have been identified and differ 
in their selectivity to ETA and ETB receptors
74. 
In short, currently several PAH-specific drugs are available, however they are not able to 
cure PAH, and some of them show adverse side effects, such as teratogenic effects, hepatic 
function deterioration and anemia during treatment75,76. 
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Animal Models of Pulmonary Hypertension 
In order to better understand the pathophysiological mechanism and remodeling 
process behind PH, and search for novel therapeutic agents, a variety of animal models have 
been developed and characterized. 
These experimental in vivo models mimic certain histological and molecular features 
seen in PH pathophysiology in humans. These include endothelial dysfunction, muscularization 
of previously non-muscular arterioles and increased medial thickness of normally muscularized 
arterioles, in situ thrombosis and plexiform lesions appearance77. Chemical agents78,79, genetic 
techniques80,81, environmental factors82 and surgical procedures83 can be used to induce PAH-
associated alterations in animals (Table 5). 
Currently, monocrotaline (MCT) administration and chronic exposure to hypoxia are the 
most widely used models of PH in translational research due to their good reproducibility and 
well described histopathology. 
MCT is a pyrrolizidine alkaloid extracted from Crotalaria spectabilis seeds and when 
administered in rats it is metabolized by several oxidases present in the liver, producing the 
reactive bifunctional cross-linking compound MCT pyrrole. Because this compound has a short 
half-life and the pulmonary circulation represents the first major vascular bed following liver, 
its toxic effect concentrate on pulmonary vessels without affecting the systemic circulation77. 
After MCT injection, rats undergo a severe inflammatory reaction, followed by EC death 
and loss of small peripheral arteries, as well as an increase of the alveoli/arteries ratio. In the 
first two weeks no clinical disorder can be noticed, whereas in the following 2-4 weeks, the 
animal’s state begins to deteriorate due to the progressive thickening of the media, 
muscularization of non-muscularized arteries, along with an adventitial proliferation. These 
abnormalities lead to a progressive increase in mPAP and PVR, ultimately leading to RV 
hypertrophy (RVH) and increased RV systolic pressure (from 25 to 80 mmHg). At this stage, 
animals show impaired breathing and cyanotic mucus membranes, acquiring also a hunched 
posture, being visibly sick. After 4-6 weeks of MCT-administration, animals develop severe PH 
with a compensatory RVH, due to the increase in PVR. Following this stage and with a 
progressive increase in PVR, the RV function deteriorates and eventually the animals die of RV 
failure. However, due to the different pharmacokinetics of MCT among different rat strains, 
and even between individuals, differences in time of onset and extent of toxic effects can be 
seen84. 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Introduction| 28  
 
TABLE 5. Experimental animal models of Pulmonary Hypertension 
 
Experimental model Animal species 
Shared pathological findings in human 
disease 
(Patho)physiological 
stimuli 
Acute and chronic 
hypoxia 
Bird, cow, dog, 
guinea pig, 
mouse, pig, rat, 
sheep 
Increased muscularization of resistance 
vessels in chronic bronchitis, cystic fibrosis, 
chronic obstructive pulmonary disease, 
hypoventilation and chronic heart disease. 
Increased flow 
Dog, pig, rat, 
sheep 
Increased muscularization in congenital 
heart disease 
Vascular obstruction 
(air embolism, 
synthetic 
microspheres) 
Dog, pig, rat, 
sheep 
Vascular obliteration and increased 
muscularization in chronic pulmonary 
thromboembolism 
Chemical and toxic 
stimuli 
Monocrotaline 
(pyrrole) 
Dog, rat, sheep 
Increased muscularization and vascular 
inflammation in drug-induced PH 
α-Naphthylthiourea Rat 
Pulmonary edema and increased 
muscularization induced by chemotherapy 
Bleomycin 
Mouse, rabbit, 
rat 
Fibrosis and increased muscularization in 
interstitial lung diseases 
Group B 
Streptococcus 
Pig, sheep 
Vasoconstriction in persistent PH of the 
newborn 
Molecular stimuli 
VEGFR-2 inhibition + 
hypoxia 
Rat Plexiform lesions in primary PH 
Angiopoietin-I 
overexpression 
Rat 
Muscularization and vascular occlusion in 
primary and secondary PH 
Genetic stimuli 
Fawn-hooded rat Rat 
Genetic predisposition resulting in increased 
muscularization 
Broiler chickens Chicken 
Genetic predisposition resulting in increased 
muscularization 
BMPR2 knockout Mouse 
Genetic predisposition resulting in increased 
muscularization 
S100A4 
overexpression 
Mouse 
Genetic predisposition resulting in plexiform 
lesions 
Abbreviations: BMPR2, bone morphogenic protein receptor type II; PH, pulmonary hypertension; VEGFR-2, vascular endothelial 
growth factor receptor type II. Adapted from Marsboom et al. (76). 
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Overview of Urocortin-2/CRHR2 System 
Urocortins (UCNs) belong to the corticotropin-releasing hormone (CRH) family which 
includes CRH, fish urotensin I, frog sauvagine, UCN-1, UCN-2 (or stresscopin-related peptide) 
and UCN-3 (or stresscopin)85. The various actions of the CRH family of peptides are mediated 
via CRH receptors (CRHRs) that derive from two distinct genes termed CRHR1 and CRHR2
86. 
These peptides and their receptors are ancient signaling molecules that allow organisms 
in development to coordinate physiological responses to a changing environment85. The CRH 
family seem to have overlapping roles in different tissues namely the immune, digestive, 
central nervous, reproductive and cardiovascular systems, with their relative importance in 
each system dependent upon their site of production, plasma distribution and specific 
receptor affinity87. 
UCN-2 is a peptide highly expressed within the cardiovascular system and has shown 
promising effects in multiple studies in both animals88-90 and humans91,92. Therefore, UCN-2 
expression and activity in the heart, particularly its therapeutic potential in terms of cardiac 
protection has gaining interest in the field of cardiovascular research. 
 
Molecular Structure 
UCN-1 is a 40 amino acid (aa) peptide related to CRH (45% sequence identity) and 
urotensin (63% sequence identity)93. The parent peptide, composed of 122 aa, has an N-
terminal methionine and a consensus signal peptide sequence, whilst the carboxy terminus of 
the precursor contains the C-terminally amidated peptide of UCN-1. The CRH analogue 
peptides have a helical conformation and the C-terminal helices are amphipathic, whereas the 
N-terminal helices differ in their amphipathicity. The amphipathic N-terminal helices might 
play an important role in selectivity of the analogues to CRHR1, but may not be as essential for 
CRHR2 binding. The link between N- and C-terminal helices could also play a fundamental role 
in ligand-receptor interactions94. 
UCN-2, a 38 aa peptide, shows reasonable homology with rat and human CRH (34%), 
UCN-1 (43%) and UCN-3 (37–40%)95. Mouse UCN-2, but not human UCN-2, is processed at the 
C terminus, resulting in an amidated residue that is further cleaved to a smaller bioactive form. 
The prohormones of both UCN-1 and UCN-2 are heavily glycosylated and are capable of 
activating CRHR2
96. 
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The CRHR1 and CRHR2 are membrane-bound proteins that belong to the class B1 of the 
family of seven transmembrane GPCRs and are encoded by two distinct genes, at least in 
mammals, which are expressed in numerous tissues. Both receptors, bind all members of the 
CRH family, albeit with different affinities97. 
Concerning receptor structure, they have an aa homology of about 70%, while exhibiting 
an approximately 47% divergence at the N-terminal extracellular domain (ECD), a major ligand 
binding site, which serves to dock peptide ligands via its C-terminal segment. This is consistent 
with their distinct actions and agonist selectivity, which is important for their unique 
physiological roles when co-expressed in the same tissue98. Early studies identified a number 
of aa within the ECD region crucial for the binding of CRHR1 receptor agonists and antagonists. 
Both CRHR1 and CRHR2 ECDs contain a short consensus repeat fold, characteristic of the ECD of 
class B1 GPCRs and important in activating the receptor by inducing a helix formation towards 
the N-terminus of the ligand to generate a conformational active state99,100. 
 
Tissue Distribution 
In the brain, UCN-1 expression is most prominent in the Edinger Westphal nucleus and 
lateral superior olive. UCN-1 mRNA or immunoreactivity has also been reported in other brain 
regions including the hypothalamus and it seems to be co-localized with dopamine. UCN-1 
distribution has also been verified in peripheral tissues such as heart, adrenal gland, skeletal 
muscles, placenta, skin, immune system, and gastrointestinal tract101. 
UCN-2 has a similar pattern of distribution relative to UCN-1 in the mouse and rat 
central nervous systems. In peripheral tissues, high levels of UCN-2 have been detected in the 
heart, adrenal gland, placenta, stomach, skin, ovaries, gastrointestinal tract, uterine smooth 
muscle, skeletal muscle and peripheral blood vessels101. 
In contrast, UCN-3 exhibits a different distribution from UCN-1 and UCN-2, since it’s 
found predominantly within the hypothalamus and amygdala. Several major UCN-3 terminal 
fields have been recognized, including the lateral septum and the ventromedial hypothalamus 
which are known to express high levels of CRHR2, supporting the notion that UCN-3 is an 
endogenous ligand101. In human peripheral tissues, immunoreactive UCN-3 is expressed in the 
adrenals, heart and kidney (particularly the distal tubules)102. 
Regarding the receptors, CRHR1 is not detected in the heart, while CRHR2 is highly 
expressed in cardiomyocytes86. In the heart, CRHR2 has two splice variants – CRHR2α which is 
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detected in all chambers of the human heart, and CRHR2β which seems to be restricted to the 
left atrium86. This latter isoform is also found in endothelial and SMCs of the systemic 
vasculature103. This observation triggered investigation of UCN-2 as an important physiological 
peptide in the cardiovascular system. 
The half-life of UCN-1 and -2 in humans is approximately 50104,105 and 10 minutes92, 
respectively. The exact half-life of UCN-3 in man is not yet known, but it appears to have a 
shorter interval of action, at least in healthy sheeps106. 
 
Intracellular Signaling Pathways 
UCN-2 appears to exert its effects mainly through interaction with CRHR2 on target cells, 
since it shows no appreciable binding affinity for the CRHR1
107. Upon agonist binding, CRHRs 
undergo a structural conformation alteration, activating the coupled heterotrimeric G protein 
which mediates a wide range of intracellular pathways101. 
The CRH family of peptides achieves its physiological effects mainly via activation of the 
adenylyl cyclase (AC)-cAMP signaling pathway108, which initiates intracellular events resulting 
in post-translational modifications of target proteins by protein kinase A (PKA) and/or other 
kinases, and alteration of gene transcription regulation by cAMP response element-binding 
(CREB) proteins109. However, some studies88,110 have shown that pharmacological inhibition of 
the cAMP/PKA pathway failed to abolish the biological effects of CRH and related agonists, 
suggesting that these peptides and their receptors are able to induce cellular events through 
alternative signaling pathways, as will be further discussed. 
Several studies suggest that signaling transduction by UCN-2 and related peptides, 
begins by an increase in cAMP-dependent PKA activity103, 111 and downstream PKA/A-kinase 
anchoring protein (AKAP) interactions112. UCN-2-binding to CRHR2 promotes an increased 
activation of extracellular-signal-regulated kinase (ERK) 1/288, 113 and exchange proteins 
activated by cAMP (EPAC), which appears to play a role in cAMP-dependent ERK1/2 
activation114, 115. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) pathway is also 
known to be activated by this peptide108, 112, 116, 117, and it is particularly important in cardiac 
and skeletal muscle since it helps regulate phospholamban (PLB) phosphorylation, along with 
PKA, controlling the inhibition of sarco/endoplasmatic reticulum calcium-ATPase (SERCA)118. 
Another signaling pathway induced by CRHR2 activation is Ca
2+/calmodulin-CaMKII, 
which along with PKA, is important for intracellular Ca2+ homeostasis given that they have the 
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ability to phosphorylate key Ca2+-regulating proteins like the L-type Ca2+ channel, the 
ryanodine receptor and PLB119. The activation of these proteins leads ultimately to increased 
Ca2+ influx, sarcoplasmic reticulum (SR) Ca2+ content and accelerated [Ca2+]i transients
119, 120. 
UCN-2 also interferes with the opening of K+ channels, leading to a hyperpolarized state, which 
increases the driving force for Ca2+ entry in the cell121. 
Regarding the NO/cGMP pathway, it seems that, in contrast to CRHR1, CRHR2 activation 
in human umbilical vein endothelial cells (HUVECs) leads to an increased expression of 
inducible NOS (iNOS)122. In pigs, UCN-2 administration induces NO release via activation of 
CRHR2
89, leading also to increased Ca2+ influx since UCN-2 causes eNOS activation through 
CRHR2-cAMP and CaMKII-dependent signaling
120. 
Recently, the mechanism that leads to eNOS phosphorylation and NO release was 
established in isolated rabbit ventricular myocytes, where CRHR2 activation through UCN-2 
caused an increase in phosphorylation of Akt (Ser473 and Thr308), eNOS (Ser1177) and ERK1/2 
(Thr202/Tyr204). It appears that the MEK1/2-ERK1/2 pathway is not required for stimulation 
of NO signaling in these cells because eNOS phosphorylation was not suppressed by inhibition 
of MEK1/2. The other two pathways, cAMP-PKA and PI3K-Akt, converge on eNOS 
phosphorylation and result in pronounced and sustained cellular NO production with 
subsequent stimulation of cGMP signaling since, when both of these pathways were inhibited, 
the UCN-2-induced increases in [NO]i were attenuated
117. 
In myocytes, UCN-2 also induces the secretion of both atrial natriuretic peptide (ANP) 
and BNP from these cells via CRHR2
123. In SMCs, UCN-induced intracellular cAMP accumulation 
contributes to increased IL-6 release, and both protein kinase C (PKC) and p38 mitogen-
activated protein kinase (MAPK) signaling cascades are involved downstream of this 
pathway124. Furthermore, in neonatal rat cardiomyocytes, this increase in IL-6 release was 
induced by CRHR2, in a NF-κB-dependent manner
125, indicating that UCNs, specifically UCN-2 
and UCN-3, could be important inflammation mediators. 
Cells overexpressing both CRHR1 and CRHR2 and treated with sauvagine, a CRH-related 
peptide, causes PKA-mediated phosphorylation of the transcription factor CREB, which is an 
important intermediary step in transduction pathways arising from activation of these 
receptors and leading to modulation of gene transcription of target cells108. In addition, 
receptor stimulation by agonist binding increases activation of ERK1/2 independently of cAMP, 
revealing the possibility that PKA and MAPK may act in concert to control gene transcription in 
CRH-responsive cells. Sauvagine is also able to increase intracellular levels of Ca2+ through both 
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mobilization of intracellular stores and influx across the plasma membrane, which are 
important for muscle contraction and relaxation108. 
Markovic et al. showed that CRHR2β endocytosis appears to be regulated by ERK1/2 
direct phosphorylation of β-arrestin1 in an auto-regulatory mechanism that influences the rate 
and extent of β-arrestin1 recruitment to the plasma membrane and interaction with CRHR2β
112. 
This mechanism induced AKAP250 translocation to the plasma membrane and interaction with 
the receptor. Furthermore, this interaction exhibits signaling selectivity since it does not 
appear to be important for activation of Akt, a mechanism that is mediated via Gi/o-dependent 
pathways involving PI3K112. 
UCN-2 differentially regulates nuclear factor of activated T-cells (NFAT) activity in cardiac 
myocytes from both normal and failing heart through the PI3K/Akt/eNOS/NO pathway126 
(Figure 1). 
 
FIGURE 1. Suggested UCN-2/CRHR2 signaling pathway in the cardiomyocyte. UCN-2 regulates 
cardiomyocyte growth and proliferation (a), homeostasis (b) and function (c). A) Upon UCN-2 binding to 
CRHR2, the activation of AC, by the α-subunit of G protein, results in an increase in cAMP concentration, 
which promotes an increased activation of PKA and EPAC. This results in post-translational modifications 
of target proteins, such as ERK1/2, and alteration of gene transcription regulation by CREB and NF-κB. B) 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Introduction| 34  
 
The Ca
2+
/calmodulin-CaMKII, along with PKA, is important for intracellular Ca
2+
 homeostasis, since they 
have the ability to phosphorylate key Ca
2+
-regulating proteins, leading to increased Ca
2+
 influx, SR Ca
2+
 
content and accelerated [Ca
2+
]i transients. The cAMP-PKA and PI3K-Akt signaling pathways converge on 
eNOS phosphorylation and result in pronounced and sustained cellular NO production with subsequent 
stimulation of cGMP signaling. C) The activation of PI3K, though the βγ subunit of the G protein, leads to 
Akt activation which helps regulate PLB phosphorylation, along with PKA, controlling the inhibition of 
SERCA. NFAT regulation is mediated by PI3K/Akt/eNOS/NO signaling cascade that converges on the 
activation of several kinases, including GSK-3β, JNK, p38 and PKG, resulting in phosphorylation, 
deactivation and nuclear export of NFAT. 
Abbreviations: AC, adenylate cyclase; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; EPAC, exchange proteins 
activated by cAMP; MEK1/2, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase; CREB, cAMP 
response element-binding protein; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; eNOS, endothelial nitric 
oxide synthase; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; CaM, calmodulin; CaMKII, Ca2+ /calmodulin-dependent 
protein kinase II; PI3K, Phosphoinositide 3-kinase; PIP3, Phosphatidylinositol (3,4,5)-trisphosphate; AKT, protein kinase B; Serca 2a, 
sarco/endoplasmic reticulum Ca2+-ATPase; PLB, phospholamban; UCN-2, Urocortin-2; CRHR2, corticotropin releasing hormone 
receptor type 2; NFAT, nuclear factor of activated T-cells; GSK-3β, glycogen synthase kinase 3 beta; JNK, c-Jun NH2-terminal 
kinase; p38, p38 mitogen-activated kinase; PKG, protein kinase G. 
 
UCN-2/CRHR2 Signaling Effects in Cardiac Function 
The majority of the described actions of UCNs in the myocardium have been revealed by 
observations in cardiomyocytes and in animal models of heart failure. However, it is not 
completely clear if the protective effects of UCNs are mediated via a direct effect on cardiac 
myocytes or via sympathetic stimulation in reaction to decreased peripheral resistance127. 
In both rabbit128 and mouse ventricular myocytes119, as well as in a murine model of 
HF129, UCN-2 administration enhances myocardial inotropy and lusitropy in a time- and 
concentration-dependent manner. These effects appear to be mediated via activation of 
CRHR2 and subsequent stimulation of both cAMP/PKA and Ca
2+/calmodulin-CaMKII signaling 
pathways since they were abolished by antisauvagine-30, a specific CRHR2 antagonist, leading 
to increased SR Ca2+ content and [Ca2+]i transients, as well as an accelerated decay of the 
latter119, 128. However, in mouse cardiomyocytes, these effects were accompanied by 
arrhythmogenic events, triggered by spontaneous diastolic SR Ca2+ release119. On the other 
hand, UCN-2 is reported to increase the ventricular fibrillation threshold130 and reduce the 
occurrence of arrhythmias131 in vivo. Evidence of the UCNs actions to improve intracellular 
handling132 and perhaps inhibit efferent cardiac sympathetic nerve activity133, might explain 
the peptide’s anti-arrhythmic effects in the whole animal. Other beneficial cardiac effects of 
UCNs include their ability to improve cardiac bioenergetics (through preservation of high-
energy phosphate stores)134. 
In the pig, local intracoronary administration of UCN-2 also has the ability to increase 
coronary blood flow as well as myocardial function89. In addition, an immediate improvement 
of left ventricular fractional shortening and circumferential fiber shortening velocity after an 
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acute injection of UCN-2 has been described in rats. These positive effects were maintained 
even at 5 weeks after treatment135. 
Recently, Walther et al. demonstrated that UCN-2 differentially regulates NFAT activity 
in cardiac myocytes from both normal and failing hearts, having a crucial role in the regulation 
of gene expression in cardiac development, maintenance of an adult differentiated cardiac 
phenotype and remodeling processes126. 
 
UCN-2/CRHR2 Signaling Effects in Vascular Function 
UCN-2/CRHR2 system effects are not limited to the heart, since in both pulmonary and 
systemic vasculature the activation of this receptor and the following pathway seems to exert 
a potent and consistent relaxation of the vessels. 
In rat thoracic aorta, UCN-2 and -3 wield more potent vasodilator effects than CRH, and 
since this relaxation response was abolished in the presence of both AC and PKA inhibitors, 
this effect is likely to be mediated by signaling pathways involving these peptides136.  
Indeed, in both healthy137 and animal models of HF129, UCN-2 administration causes a 
reduction in arterial blood pressure. Furthermore, the selective CRHR2 antagonist, astressin2-B, 
abolished UCN-2-induced hypotensive activity while having no effect on basal arterial blood 
pressure, indicating that UCN-2 induces hypotension through peripheral CRHR2
137. Dieterle et 
al. also showed an immediate and sustained lowering of blood pressure in hypertensive rats, 
with no reflex rise in HR135. Several mechanisms have been postulated for the blood pressure-
lowering effects of the UCNs, including a direct smooth muscle relaxant effect in combination 
with an associated reduction in plasma concentrations of vasoconstrictor hormones. Grossini 
et al. showed that UCN-2 administration in the anaesthetized pig primarily increases coronary 
blood flow and myocardial function through the release of NO and activation of CRHR2. In this 
study, the blockade of NOS abolished only the coronary effects, whereas blockade of subtype 2 
of the CRH receptors abolished both cardiac and coronary effects89. 
Ex vivo studies in human internal mammary artery138 and in rat coronary artery139 
propose both endothelium-dependent and -independent mechanisms for vasorelaxation, 
which involves the release of NO that in turn stimulates Ca2+-activated K+ channels in vascular 
smooth muscle via cGMP-dependent pathways138. 
Additionally, another important role for the UCN-2/CRHR2 system is its contribution to 
the angiogenesis process, being a critical component of the pathway necessary for tonic 
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inhibition of adult neo-vascularization. Bale et al. demonstrated that mice deficient in CRHR2 
become hypervascularized postnatally. On the other hand, the activation of this receptor in 
vitro results in reduced release of VEGF from SMCs, inhibition of SMC proliferation and 
inhibition of capillary tube formation in collagen gels140.  
Recently, Emeto et al. reported that in human aortic vascular SMCs, UCN-2 significantly 
inhibited Akt phosphorylation and proliferation in a dose-dependent manner by promoting a 
G1 cell-cycle arrest, reinforcing the role of UCN-2 in the regulation of cell proliferation
141. 
Moreover, endothelial UCN has potent antioxidative properties and is up-regulated by 
inflammatory cytokines and pitavastatin142. 
 
UCN-2/CRHR2 Signaling Effects in Heart Failure 
Given the potent vasorelaxant and inotropic effects of UCN-2, interest has grown in its 
role in the pathophysiology of HF and its potential therapeutic value in this disease. Several 
studies with UCN-2 in different animal models and in human clinical studies have 
demonstrated the beneficial effects of the peptide in the setting of cardiac failure. 
In both adult rabbit ventricular myocytes128 and in a murine model of HF129, UCN-2 
administration enhanced myocardial inotropy and lusitropy, increasing cell shortening and 
accelerating relaxation in a time- and concentration-dependent manner. These effects are 
induced via CRHR2 receptor-mediated stimulation of PKA
128. 
In contrast to limited UCN-2 bioactivity in healthy sheep, the therapeutic administration 
in animals with pacing-induced HF induced rapid and dose-dependent increases in CO and 
reductions in peripheral resistance and left atrial pressure90. The prolonged administration of 
UCN-2 in the same animal model also produced the beneficial effects seen above, except in a 
sustained way of action143, supporting a role for UCN-2 in pressure/volume homeostasis in HF. 
Additionally, UCN-2 co-treatment with an existing proven treatment such as furosemide, a 
diuretic agent, resulted in enhancement of beneficial hemodynamic effects compared with 
either agent alone, together with augmented renal responses with less rennin activation and 
no exacerbation of potassium loss144. 
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UCN-2/CRHR2 Signaling Effects in Myocardial Ischemia 
Myocardial ischemia frequently leads to cardiomyocyte apoptosis and necrosis, even 
with subsequent restoration of blood flow to the affected area, which has caused research to 
focus on trying to prevent cardiomyocyte death after an ischemic event. In this context, UCNs 
appear to have a cardioprotective role with increased expression and peptide release observed 
following ischemia stimulation145. 
On the other hand, neonatal cardiomyocytes treated with either 1-10nM of UCN-2 or -3 
results in ERK1/2 phosphorylation, and the inhibition of MEK 1/2 obstructs their 
cardioprotective effects88. Brar et al. suggested that UCN-2 and -3 have a cardioprotective role 
in situations of ischemia/reperfusion injury acting via the MAPK pathway and reducing infarct 
size88. 
Moreover, as mentioned above, CRHR2-deficient mice become hypervascularized 
postnatally and the activation of this receptor reduces VEGF release from SMCs, suppresses 
SMC proliferation and impedes capillary tube formation140. These studies demonstrate a 
critical role for CRHR2 in the regulation of angiogenesis and remodeling of both juvenile and 
adult vasculature, suggesting this receptor may be a potential target to modulate angiogenesis 
in diseases such as cardiovascular ischemia. 
 
UCN-2/CRHR2 Signaling Effects in Other Cardiovascular Diseases 
Dieterle et al. reported that chronic UCN-2 treatment was able to improve cardiac and 
vascular function through an immediate sustained blood pressure reduction without affecting 
the HR. Furthermore, long-term UCN-2 treatment in hypertensive rats diminishes the 
development of hypertension-induced LV hypertrophy and the deterioration of its contractile 
function135. Moreover, long-term UCN treatment not only had hypotensive effects but may 
also inhibited development of vascular remodeling in mesenteric arteries in spontaneously 
hypertensive rats146. These beneficial effects of UCN-2 may represent a novel approach for 
antihypertensive therapy. 
In a recent study, patients who underwent coronary angiography with the pre-diagnosis 
of coronary artery disease were examined and distributed according to their ejection fraction 
(EF). Those patients with moderate to severe systolic dysfunction (SD) showed decreased 
serum UCN-2 levels, while patients with mild to moderate SD showed increased levels of the 
peptide when compared to patients without SD. In contrast, the presence of diastolic 
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dysfunction or coronary artery disease appeared to have little effect on circulating UCN-2 
concentrations147. 
 
Urocortin-2 as a Therapy for Heart Failure in Humans 
Recently, a small number of clinical studies in humans have confirmed some data 
obtained from animal studies. In fact, UCN-2 administration in healthy humans induces a dose-
related increase in CO, HR and left ventricular ejection fraction (LVEF) in association with 
decreased systemic vascular resistance92. Moreover, UCN-2 and -3 promotes a potent 
prolonged arterial vasodilatation without causing tachyphylaxis, with these effects being partly 
dependent on endothelial NO and cytochrome P450 metabolites of arachidonic acid148. 
In humans with both mild149 and acute decompensated HF91, UCN-2 administration 
resulted in a markedly augmented CO without significant reflex tachycardia and an improved 
vascular function. Pronounced falls in systemic arterial pressure were also seen with higher 
doses of UCN-291. UCN-2 also induced vasorelaxation of coronary arteries isolated from 
patients with HF, independently of endothelial integrity150. In addition to positive effects on 
cardiovascular parameters when used as a treatment in HF, UCNs may also serve as possible 
biomarkers in the identification of early HF151. 
Based on these clinical studies, detailed in Table 6, it appears that UCN-2, alone or in 
combined therapy, is able to regulate the cardiovascular system which points towards a 
therapeutic application for this peptide in HF. 
 
TABLE 6. Clinical trials with Urocortin-2 as a therapy for Heart Failure 
Refs Model Treatment Outcome 
92
 
8 Healthy 
humans 
Subjects received placebo, 25μg and 100μg of 
UCN-2 intravenously over the course of 1h. 
↑ Cardiac output; 
↑ Heart rate; 
↑Left ventricular ejection fraction; 
↓ Systemic vascular resistance. 
148
 
18 Healthy 
humans 
Volunteers were subjected to a bilateral forearm 
venous occlusion plethysmography during intra-
arterial UCN-2 (3.6-120pmol/min), UCN-3 (1.2-
36nmol/min) and substance P (2-8pmol/min). 
Potent and prolonged arterial 
vasodilatation without 
tachyphylaxis. 
149
 
8 Male 
patients 
with HF 
Received placebo and 25μg and 100μg of UCN-2 
intravenously over 1h. 
↑ Cardiac output; 
↑ Left ventricular ejection fraction; 
↓ Mean arterial pressure; 
↓ Systemic vascular resistance; 
↓ Cardiac work. 
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Other Biological Effects of Urocortin-2 
UCN-2 is also expressed in the central nervous system and it seems to be involved in the 
regulation of the stress response, anxiety and depression152, as well as in the control of 
appetite98. Male, but not female, UCN-2-knockout animals demonstrate an altered social 
behavior, with more passive social interactions and reduced aggressiveness in comparison to 
wild-type animals. Moreover, UCN-2 appears to modulate the aggressive behavior in male 
mice153 further evidence that this peptide is involved in the regulation of stress-related 
behaviors. 
In terms of appetite control, a recent study has reported that CRHR1 agonists, UCN-1 and 
stressin1-A, reduced feeding and induced interoceptive stress, while UCN-2 had a more potent 
suppressive effect on feeding, via a CRHR2-dependent mechanism, without eliciting malaise
154. 
UCN-2 also appears to be responsible for a decrease in gastric emptying152 which aids in 
appetite inhibition. These differences between UCNs in their regulation of these various 
functions seem to be consistent with their pharmacological differences. 
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AIMS 
Based on the published findings referenced in the previous chapter, we hypothesize that 
by activating CRHR2 in animals with PAH, through UCN-2 administration, we might protect not 
only the pulmonary vasculature, but also the RV myocardium and thus increase animal 
survival, attenuate PAH severity and improve RV function. 
Therefore, we purpose to investigate the role of the UCN-2/CRHR2 system in the 
pathophysiology of PAH and progression to HF, while evaluating the efficacy of UCN-2 as a 
possible novel therapeutic strategy for this disease. 
 
Our specific goals are: 
1. to determine changes in the expression of UCN-2 and its receptor, and of downstream 
signaling pathways in the heart tissue from healthy rats and from rats with PAH induced by 
monocrotaline (MCT); 
2. to assess changes in animal survival, RV myocardial function and the severity of PAH in vivo 
(hemodynamic and echocardiographic studies),  changes in myocardial structure and 
histology and its patterns of gene expression, in healthy animals and in animals with PAH 
and HF with or without chronic UCN-2 treatment. 
  
 
 
 
 
 
METHODS 
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All the procedures in this work followed the recommendations of the Guide for the Care 
and Use of Laboratory Animals, published by the US National Institutes of Health (NIH 
Publication No. 85-23, Revised 1996), and are accredited by the Portuguese Direção Geral de 
Alimentação e Veterinária (DGAV) and approved by Fundação para a Ciência e a Tecnologia 
(FCT PTDC/DTP-FTO/0130/2012). 
 
Animal Model 
Animals were grouped 3 per cage, in a controlled environment with a light-darkness 
cycle of 12:12h and an established temperature of 22ºC, with water and food ad libitum. 
Before MCT administration an echocardiographic evaluation was performed as a guarantee 
that the potentially ill animals (with cardiac disease) did not follow the protocol. Between 24 
to 25 days after MCT administration, the animals were submitted again to an 
echocardiographic study and to invasive hemodynamic evaluation. After morphometric 
assessment, samples were collected and processed for histological and molecular biology 
studies. 
Seven week-old male Wistar rats (Charles River Laboratories, Barcelona, Spain) weighing 
180-200g, were randomly assigned to receive either a subcutaneous (s.c.) injection of MCT 
(60mg/kg, Sigma-Aldrich) or an equal volume of vehicle, sodium chloride (NaCl, B. Braun, 
0.9%). A freshly aqueous solution of MCT was prepared, wherein 300mg was dissolved in 
2.36mL of 1M HCl, diluted with distilled water to about 1.60mL and neutralized with 1.52mL of 
1M NaOH. The pH was settled at 7.00. 
Fourteen days after MCT/vehicle administration, animals were randomly assigned into 4 
subgroups: CTRL, untreated animals; MCT, animals with induced PAH and without 
pharmacological treatment; CTRL + UCN-2, animals without PAH and with UCN-2 treatment; 
MCT + UCN-2, animals with induced PAH and with UCN-2 treatment. The pharmacological 
treatment consisted on a daily intraperitoneal (i.p.) injection of 2.5μg/kg twice a day of hUCN-
2 (Bachem, Bubendorf, Switzerland) during 10 days, while the vehicle treatment consisted on 
sodium chloride. 
The drug dosages, administration routes and treatment duration were selected based 
on previous studies from other research teams135 and on our preliminary dose-finding studies 
(unpublished data). Moreover and according with Reagan-Shaw’s equation155 (depicted below 
in which animal km=37 and human km=6) the UCN-2 dose administered in our animals is the 
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same that has been used in human clinical trials92, 149. Initially an aqueous solution of hUCN-2 
was prepared by dissolving 1mg in 1mL of NaCl. Part of the stock was diluted again in NaCl 
until we reach a final work concentration of 0.002mg/mL. 
                                                 
        
       
 
 
Functional Studies 
Cardiac function was evaluated both in healthy and MCT-induced PAH animals, with or 
without pharmacological treatment, in order to clarify the involvement of UCN-2/CRHR2 
system not only in the pathophysiology of PAH, but also in the progression of functional RV 
changes that accompany PAH and lead to HF. 
The echocardiographic assessment allowed for a non-invasive monitoring and 
characterization of PAH progression and ventricular function in the different experimental 
groups. Invasive hemodynamic evaluation was performed using high-fidelity pressure-volume 
catheters that provided us an accurate determination of systolic and diastolic function 
parameters. 
 
Echocardiography Studies 
For this purpose, animals from the different experimental groups were sedated with 
100μg/kg fentanyl and 5mg/kg midazolam via i.p. injection and anesthetized by inhalation of 
8% sevoflurane (Penlon Sigma Delta, UK) in vented containers. Endotracheal intubation was 
performed using a 14 gauge catheter and mechanical ventilation controlled by a rodent 
ventilator (MouseVent G500, Kent Scientific, Connecticut, USA) with an animal weight-defined 
tidal volume. Anesthesia was maintained with 2.5-3.0% vol/vol sevoflurane, titrated according 
to the toe pinch reflex. 
Animals were placed in left lateral decubitus. After applying warm echocardiography gel, 
a 15MHz sensorial probe (Sequoia 15L8W) was gently placed on the thorax. Acquisitions 
(Siemens Acuson Sequoia C512) were averaged from three consecutive heartbeats. Bi-
dimensional and M-mode images were obtained for determination of RV structure and 
function, respectively. End-diastolic dimension (RVEDD), RAA and TAPSE were obtained in 
apical projection of 4 cavities. Pulmonary artery diameter (PAD) was measured in parasternal 
short-axis view. Conventional Doppler was used to evaluate pulmonary blood flow, with the 
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determination of pulmonary artery acceleration (PAAT) and ejection (PAET) times, peak 
systolic velocity (PAPSV) and the velocity time integral (PAVTI). The PAAT/PAET ratio was 
determined, and the SV, CO and cardiac index (CI) were calculated as follows: 
                
   
 
 
 
  
                         
                
  
              
 
 
Invasive Hemodynamic Evaluation 
After the echocardiographic evaluation, and as previously described156, the animal 
position was adjusted to right lateral decubitus for proper orientation of the heart for 
instrumentation. Animal temperature was monitored and regulated with a warming pad and a 
rectal temperature sensor, and digitally controlled together with pulse oxymetry measured 
through a paw sensor (PhysioSuite, Kent Scientific, Connecticut, USA), and ECG (Animal Bio 
Amp, ADinstruments, Oxford, UK) (shown in Figure 5A). Anesthesia was maintained with 
sevoflurane (2.5-3.0% vol/vol). 
The internal femoral vein was catheterized using a 24G catheter, under surgical 
microdissection (Wilde M651, Leica microsystems, Cambridge, UK) for infusion (Multi-Phaser, 
NE-100, New Era Pump Systems, NY, USA) of warm lactate Ringer’s solution at a rate of 
32mL/kg/h (Figure 5B and 5C). A left thoracotomy was performed, pericardium and pleura 
were carefully dissected and the phrenic nerve was severed (Figure 5D). A 3-0 surgical silk was 
passed around the inferior vena cava (IVC) for transient occlusion during the protocol. 
Pressure-volume catheters were inserted through the apex of the RV and positioned along the 
long axis (SPR-869, Millar Instruments, Texas, USA). A flow probe was implanted around the 
ascending aorta (MA2.5PSB, 2.5mm, Precision S-Series, Transonic Systems, NY, USA) and 
connected to an ultrasonic transit time volume flowmeter (TS420, transit-time perivascular 
flowmeter, Transonic Systems, NY, USA). The experimental preparation was allowed to 
stabilize for 15 minutes, and during the procedure blood loss was controlled through saline 
bolus. 
Baseline and IVC occlusions recordings were obtained with ventilation suspended at 
end-expiration. Pressure and volume signals were continuously acquired (MVPS 300, Millar 
instruments, Texas, USA), digitally recorded at a sampling rate of 1000Hz (ML880 PowerLab 
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16/30, ADInstruments, Oxford, UK) and analyzed off-line (LabChart 7 Pro, ADInstruments, 
Oxford, UK, and PVAN 3.5, Millar Instruments, Texas, USA). Parallel conductance for the 
volume catheter was computed after bolus injection of 50μL hypertonic saline (10% sodium 
chloride) and the calibration for factor alpha (field inhomogeneity) was determined through 
the CO measured by the aortic flow probe and the ultrasonic transit time volume flowmeter. 
Following anesthetic overdose, blood was retrieved for storage and further analysis. 
Animals were exsanguinated and heparinized blood was collected and used for volume 
calibration with standard cuvettes (P/N 910-1048, Millar Instruments, Texas, USA). 
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FIGURE 2. Preparation of the rat for the hemodynamic evaluation. A) Position of the rat for the 
hemodynamic instrumentation, B) femoral vein exposure and dissection and C) IV catheter placement 
and D) thorax exposure after left thoracotomy. 
 
The baseline hemodynamic parameters analyzed were: HR, CO, RV end-systolic (ESP) 
and end-diastolic (EDP) pressure, end-diastolic volume (EDV), SV, EF and the isovolumic 
relaxation constant (τlog). IVC occlusion-derived end-systolic (ESPVR Ees) and end-diastolic 
(EDPVR k1) pressure volume relantionship slopes were also determined. PVR was calculated as 
follows: 
           
 
Morphometric and Histological Analysis 
RV structural alterations, such as hypertrophy, are associated with PAH-progression157, 
therefore morphometric and histological analysis was mandatory in this context. 
Immediately after exsanguination of the anesthetized/instrumented animal, heart, 
lungs, liver and gastrocnemius were excised and weighted. RV and LV + Septum (LV+S) were 
carefully dissected and weighted separately. Although tissue weight is usually normalized to 
the animal body weight, HF is associated with cachexia158 and therefore, normalizing tissue 
weights of MCT-injected animals might lead to an overestimate of cardiac hypertrophy. In 
order to eliminate bodyweight as a confounding factor in tissue weight normalization, tibia 
length, which remains constant throughout adulthood, was measured and served as a 
normalizer159.  
Samples for histology were submersed in a fixative solution of 10% formaldehyde. After 
the initial fixation step, samples underwent dehydration (using ethanol in decreasing 
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percentages), diaphanisation (using xylene) and impregnation in liquid paraffin (54ºC). Later 
they were placed and properly oriented in metal molds and serial sections of 4μm were 
obtained from RV samples, in a Minot-type microtome. Hematoxylin and eosin (HE) stained 
sections of the RV were used to measure cardiomyocyte cross-sectional area. Sections were 
digitally photographed (Olympus XC30 Digital colour Camera, Olympus, PA, USA) and 
measured using imaging software (cellB, Olympus, PA, USA). Fifty muscle fibers per animal 
were analyzed and only nuclei-centered cardiomyocyte were considered for analysis of 
cardiomyocyte dimensions. 
 
Molecular Studies 
These studies focused on the gene expression and protein activation analysis of the 
main components of UCN-2/CRHR2 system (peptide, receptors and downstream signaling 
pathways) as well as of known markers of heart failure in the different experimental groups. 
 
mRNA Expression 
In order to allow posterior molecular analysis, RV samples were collected and stored in 
RNAlater (Quiagen), frozen in liquid nitrogen and kept at -80ºC until manipulation. RNA was 
completely extracted by the silicon membrane and guanidinium-thiocyanate method (RNeasy 
Mini Kit, Quiagen, 74104), according to the manufacturer’s instructions. Concentration and 
purity of RNA were measured by NanoDrop® ND-1000 spectrophotometer (Thermo Fisher 
Scientific), assuming as ideal ratio values of A260/A280 between 1.8 and 2.1. mRNA relative 
expression quantification was performed by two-step Real-Time Polymerase Chain Reaction 
(RT-PCR). Using animal samples from the CTRL group, standard curves were built to all the 
studied genes and tissues, correlating the initial total mRNA quantity and the threshold cycle. 
Reverse transcription was performed in a conventional thermocycler (Whatmann Biometra, 
050-901) and consisted in 10 minutes at 22ºC, 50 minutes at 50ºC, and 10 minutes at 95ºC. 
Ten percent of the obtained cDNA was amplified and detected by RT-PCR (Step-One™ Applied 
biosystems) using the probe SYBR Green (PerfeCta® SYBR Green FastMix, Rox, Kit, Quanta 
Biosciences) according to the manufacturer’s instructions. 
Amplification curves were analyzed with the equipment software (v2.2.2) through 
absolute quantification. Melting curves of each PCR reaction were used in order to exclude the 
formation of primer-dimers and unspecific products, confirming the purity of the amplified 
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product. GAPDH was chosen as reference gene, since no significant changes were observed in 
the different groups. Final gene expression results were presented in Arbitrary Units (AU), 
being the CTRL group means values after GAPDH normalization correspondent to 1AU. All 
assays were performed twice, in order to ensure the security of the obtained results. The 
primers used in the molecular analysis (Table 7) were designed in-house with appropriate 
software (DNAstar™). 
 
TABLE 7. List of used primers 
Gene Primers Sequence 
GAPDH 
P1- 
5’
TGG CCT TCC GTG TTC CTA CCC
3’
 
P2- 
5’
CCG CCT GCT TCA CCA CCT TCT
3’
 
UCN-2 
P1- 
5’
CGT TGG CAT AAC GCC TCA C
3’
 
P2- 
5’
GGA CAC AGA GCT GGG AGT TG
3’
 
CRHR2 
P1- 
5’
TGC AAC TCA TCG ACC ACG AA
3’
 
P2- 
5’
CAG GTA GCA GCC TTC CAC AA
3’
 
ET-1 
P1- 
5’
CGG GGC TCT GTA GTC AAT GTG
3’
 
P2- 
5’
CCA TGC AGA AAG GCG AAT GTG
3’
 
BNP 
P1- 
5’
CAG AGC TGG GGA AAG AAG AG
3’
 
P2- 
5’
GGA CCA AGG CCC TAC AAA AGA
3’
 
HIF-1α 
P1- 
5’
TCA TAG GCG GTT TCT TGT AGC
3’
 
P2- 
5’
CTA ACA AGC CGG AGG AC
3’
 
Caspase-3 
P1- 
5’
CGG GTG CGG TAG AGT AAG
3’
 
P2- 
5’
CTG GAC TGC GGT ATT GAG ACA
3’
 
Caspase-8 
P1- 
5’
ACC AAA TGA AGA GCA AAC CTC G
3’
 
P2- 
5’
TTT TCT GTC CCG CAT GTT GC
3’
 
Abbreviation: BNP, brain natriuretic peptide; CRHR2, corticotrophin-releasing hormone receptor type 2; ET-1, endothelin 1; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HIF-1α, hipoxia inducible factor 1 alpha; UCN-2, urocortin-2. 
 
Protein Expression 
Samples from RV of each animal were homogenized on ice in 300μL RIPA lysis buffer 
(Cell Signaling Technology) containing protease inhibitors (Protease Inhibitor Cocktail, Sigma-
Aldrich, St. Louis, USA), and phosphatase inhibitors (Phosphatase Inhibitor Cocktail 2 and 3, 
Sigma-Aldrich, St. Louis, USA). Tissue was then centrifuged at 12.000 RPMs for 20 min at 4°C. 
Supernatants were collected, and total protein concentration was determined using the 
Bradford assay (Bio-Rad Laboratories, CA, USA). Samples were treated with Laemmli loading 
buffer (Cell Signaling Technology) and boiled for 5 minutes at 95ºC. Samples, with 20μg of 
protein, were loaded onto a 10% SDS-PAGE gel (Bio-Rad Laboratories, CA, USA), run, and 
electroblotted onto a 0.2μm nitrocellulose membrane (Bio-Rad Laboratories, CA, USA). Pre-
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stained molecular weight marker proteins (Bio-Rad Laboratories, CA, USA) were used as size 
standards for the SDS-PAGE. Ponceau staining was performed to verify the quality of the 
transfer and to ensure equal protein loading. Blots were blocked in 5% BSA (Bovine Serum 
Albumin, Sigma-Aldrich, St. Louis, USA) for 1 hour at room temperature. Incubated overnight 
at 4ºC with the antibodies listed in Table 8, in separate experiences, at a dilution of 1:1000. 
 
TABLE 8. List of used primary antibodies 
Protein Antibody’s Identification 
Akt 
p-Akt 
Akt (pan) (C67E7), Rabbit mAb, Cell Signaling Technology 
Phospho-Akt (Ser473) (587F11), Mouse mAb, Cell Signaling Technology 
ERK1/2 
p-ERK1/2 
p44/42 MAPK (Erk1/2) (3A7), Mouse mAb, Cell Signaling Technology 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Rabbit pAb, Cell Signaling Technology 
p38 
p-p38 
p38α MAPK (L53F8), Mouse mAb, Cell Signaling Technology 
Phospho-p38 MAPK (Thr180/Tyr182) (D3F9), Rabbit mAb, Cell Signaling Technology 
STAT3 
p-STAT3 
Stat3 (124H6), Mouse mAb, Cell Signaling Technology 
Phospho-Stat3 (Tyr705) (D3A7), Rabbit mAb, Cell Signaling Technology 
CRHR2 Anti-Corticotropin Releasing Factor Receptor 2, Rabbit pAb, Abcam, Cambridge, UK 
GAPDH GAPDH (0411), Mouse mAb, Santa Cruz Biotechnology, Inc. 
Abbreviation: Akt, protein kinase B; CRHR2, corticotropin-releasing hormone receptor type 2; ERK1/2, extracellular-signal 
regulated kinases 1 and 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSK-3β, glycogen synthase kinase 3 beta; p38, 
p38 mitogen-activated protein kinase; STAT3, signal transducer and activator of transcription 3. 
 
After primary antibody removal, membranes were washed with Tris-Buffered Saline (Cell 
Signaling Technology) with 0.01% Tween-20 – TBS-T (Sigma-Aldrich, St. Louis, USA) and 
incubated with secondary antibodies (IRDye 680LT, Goat-anti-Mouse Ab and 800CW, Goat-
anti-Rabbit Ab, LI-COR Biosciences, Lincoln, USA) in 2% skimmed nonfat milk at a 1:25000 
dilution for 1 hour at room temperature. After washing the membranes with TBS-T, 
membranes were scanned using an Odyssey scanner (infrared imaging system, LI-COR 
Biosciences, Lincoln, USA) and analyzed using the Odyssey provided software (version 3.0). 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Software (vs.6). 2-way ANOVA was 
used to statistically analyze all the presented parameters. Holm-Sidak’s method for post hoc 
comparisons between groups and Kaplan-Meier survival analysis (log-rank test) were 
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performed. Group data are presented as means ± SEM. Differences with p<0.05 were 
considered statistically significant. 
  
 
 
 
 
 
RESULTS 
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Survival Analysis 
Excluding animals that underwent terminal hemodynamic evaluation, Kaplan-Meier 
analysis demonstrated that the survival rate for MCT treated animals was significantly higher 
(76%) when compared with MCT untreated animals (44%) as is demonstrated in Figure 3. 
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FIGURE 3. Kaplan-Meier survival curves. MCT rats treated with UCN-2 had a significantly higher survival 
rate than MCT rats (log-rank test, P=0.008). CTRL (n=13); CTRL+UCN-2 (n=10); MCT (n=10) and 
MCT+UCN-2 (n=15). 
 
Functional Studies 
Echocardiographic Evaluation 
The full echocardiographic study is presented in Table 9. The bi-dimensional analysis 
showed that MCT-treated animals developed RH dilation, as shown by an increase in RV end-
diastolic diameter (RVEDD) and right atria area (RAA), as well as a deviation of the 
interventricular septum (IVS) towards the left side of the heart (Figure 4B), while treatment 
attenuated RH structural alterations (Figure 4C). Echo-measured RV function was also 
improved with UCN-2 treatment, as measured by M-mode through the tricuspid annular plane 
systolic excursion (TAPSE), which was decreased in MCT animals. 
Doppler imaging analysis revealed a deficit in the pulmonary flow in the MCT group with 
decreased peak systolic velocity (PAPSV), pulmonary artery acceleration time (PAAT) and 
ejection time (PAET), when compared with healthy animals, which affected the PAAT/PAET 
ratio. Treatment with UCN-2 improved blood flow in the pulmonary artery, with normalization 
of the PAAT/PAET ratio. Moreover, indexes of overall cardiac function, such as CO and CI, were 
also improved with pharmacological UCN-2 intervention. 
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TABLE 9. Echocardiographic evaluation 
Echocardiographic 
Parameters 
CTRL MCT 
Vehicle UCN-2 Vehicle UCN-2 
PAPSV (m/s) 0.98 ± 0.06 0.96 ± 0.04 0.79 ± 0.03* 0.80 ± 0.04* 
PAAT (ms) 25.7 ± 2.61 31.7 ± 1.87* 13.6 ± 0.57* 20.0 ± 1.11
#
 
PAET (ms) 81.8 ± 2.46 78.3 ± 1.43 68.3 ± 1.69* 75.9 ± 1.79
#
 
RAA (cm
2
) 0.17 ± 0.01 0.20 ± 0.02 0.30 ± 0.03* 0.22 ± 0.01
#
 
RVEDD (cm) 0.39 ± 0.01 0.37 ± 0.01 0.50 ± 0.01* 0.45 ± 0.01*
#
 
TAPSE (cm) 0.23 ± 0.01 0.25 ± 0.01 0.12 ± 0.02* 0.18 ± 0.01*
#
 
PAAT/PAET 0.28 ± 0.04 0.40 ± 0.02* 0.20 ± 0.01* 0.26 ± 0.01
#
 
CO (mL/min) 168 ± 22.4 176 ± 14.0 86.3 ± 14.7* 137 ± 10.4*
#
 
CI (mL/min/100g BW) 56.4 ± 7.1 59.6 ± 5.1 33.1 ± 4.6* 52.3 ± 3.9
#
 
CTRL (n=13); CTRL+UCN-2 (n=10); MCT (n=10) and MCT+UCN-2 (n=15). Abbreviations: BW, body weight; CI, cardiac index; CO, 
cardiac output; PAAT, pulmonary artery acceleration time; PAET, pulmonary artery ejection time; PAPSV, pulmonary artery peak 
systolic velocity; RAA, right atria area; RVEDD, right ventricle end-diastolic diameter; TAPSE, tricuspid annular plane systolic 
excursion. *p<0.05 vs CTRL, #p<0.05 vs MCT. 
 
 
FIGURE 4. Representative echocardiographic images. Representative images from the CTRL (A), MCT (B) 
and MCT+UCN-2 (C) groups showing an apical 4-chamber view. MCT animals reveal RV hypertrophy and 
deviation of the IVS (indicated by the white line) to the left side of the heart (B). Treatment with UCN-2 
restored both RV dilation and IVS structure (C). CTRL (n=13); CTRL+UCN-2 (n=10); MCT (n=10) and 
MCT+UCN-2 (n=15). Abbreviations: IVS, interventricular septum; LA, left atrium; LV, left ventricle; RA, 
right atrium and RV, right ventricle. 
 
Invasive Hemodynamic Analysis 
The complete hemodynamic study is detailed in Table 10 and representative pressure-
volume loops are shown in Figure 5. Baseline RV hemodynamics revealed impaired RV function 
with both systolic and diastolic alterations in non-treated PAH animals. The MCT group 
presented a lower HR and decreased CO. Pulmonary resistances (PVR), representative of 
increased RV overload, were also increased in the MCT group. Moreover, systolic function was 
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deteriorated with increased end-systolic pressure (ESP) and decreased ejection fraction (EF), as 
well as higher IVC occlusion-derived end-systolic pressure volume relationship slope (ESPVR 
Ees). Diastolic impairment was also evident in MCT animals. End-diastolic pressure (EDP) and 
the isovolumic relaxation time constant (τ) were elevated in these animals. The load-
independent end-diastolic pressure volume relationship slope (EDPVR k1) was also increased in 
the MCT group when compared to controls. RV dilation was obvious with increased end-
diastolic volumes (EDV) and a compromised SV, representative of the deteriorated ventricular 
function in these animals. Treatment with UCN-2 reversed RV dilation and improved both 
systolic and diastolic function, resulting in an overall improved right ventricular structure and 
function. 
 
TABLE 10. Invasive hemodynamic evaluation 
Hemodynamic 
Parameters 
CTRL MCT 
Vehicle UCN-2 Vehicle UCN-2 
HR (bmp) 387 ± 6 381 ± 3 357 ± 13* 383 ± 11
#
 
CO (mL/min) 64.4 ± 2.6 64.4 ± 3.2 34.5 ± 5.6* 46.6 ± 2.2*
#
 
Baseline RV 
ESP (mmHg) 22.3 ± 0.8 22.9 ± 1.0 59.7 ± 2.5* 47.6 ± 3.6*
#
 
EDP (mmHg) 3.7 ± 0.3 4.0 ± 0.3 6.0 ± 0.7* 4.3 ± 0.3
#
 
EDV (μL) 222.1 ± 11.2 230.2 ± 9.4 280.0 ± 13.5* 212.9 ± 12.2
#
 
SV (μL) 167.2 ± 7.4 178.2 ± 9.1 91.8 ± 12.5* 121.6 ± 4.8*
#
 
EF (%) 74.6 ± 2.6 72.9 ± 3.4 32.1 ± 3.5* 59.5 ± 2.7*
#
 
τlog (ms) 7.18 ± 0.78 7.35 ± 0.78 9.60 ± 0.85* 7.76 ± 0.51*
#
 
PVR 
(mmHg/mL/min) 
0.35 ± 0.02 0.36 ± 0.02 2.02 ± 0.16* 1.07 ± 0.11*
#
 
Pressure-volume Relationships
$
 
ESPVR Ees 
(mmHg/μL) 
0.081 ± 0.007 0.083 ± 0.008 0.288 ± 0.029* 0.213 ± 0.022*
#
 
EDPVR k1 0.0065 ± 0.0008 0.0056 ± 0.0009 0.0151 ± 0.0026* 0.0095 ± 0.0020*
#
 
$Obtained by IVC occlusions. CTRL (n=13); CTRL+UCN-2 (n=10); MCT (n=10) and MCT+UCN-2 (n=15). Abbreviations: CO, cardiac 
output; EDP, end-diastolic pressure; EDV, end-diastolic volume; EDPVR k1, end-diastolic pressure-volume relationship’s slope; EF, 
ejection fraction; ESP, end-systolic pressure; ESPVR Ees, end-systolic pressure-volume relationship’s slope; HR, heart rate; PVR, 
pulmonary vascular resistance; SV, stroke volume; τlog, isovolumic relaxation time constant. *p<0.05 vs CTRL, 
#p<0.05 vs MCT. 
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FIGURE 5. Representative pressure-volume loops. Representative pressure-volume loops of the different 
study groups, obtained by transient inferior vena cava (IVC) occlusions. MCT untreated animals revealed 
higher EDP and EDV while treatment with UCN-2 was able to attenuate both. 
 
Morphometric and Histological Analysis 
Animals from the MCT group presented RV hypertrophy as shown by the increase in RV 
weight (RVW)/LV + Septum weight (LV+SW) and RVW/tibia length (TL) ratios. Lung weight (LW) 
was also increased and gastrocnemius weight (GcW) was decreased (decreased GcW/TL ratio) 
in the animals from this group. Liver weight (LiW) showed no difference between groups. UCN-
2 treated animals presented decreased RV hypertrophy and no changes in both lung and liver 
weight compared with MCT animals (Table 11). RV hypertrophy in the MCT group, was further 
confirmed by histological measurement of cardiomyocyte cross-sectional area (CSA) (MCT: 366 
± 25 μm2) when compared to CTRL (255 ± 26 μm2). UCN-2 treatment was capable to reverse 
MCT-induced hypertrophy (MCT+UCN-2: 287 ± 26 μm2) (Figure 6). 
 
TABLE 11. Morphometrical analysis 
Morphometric Ratios 
CTRL MCT 
Vehicle UCN-2 Vehicle UCN-2 
HW/BW (g/kg) 2.48 ± 0.06 2.50 ± 0.04 3.53 ± 0.15* 3.03 ± 0.10*
#
 
RVW//LV+SW (g/g) 0.26 ± 0.01 0.26 ± 0.01 0.48 ± 0.02* 0.41 ± 0.02*
#
 
RVW/TL (g/cm) 0.04 ± 0.00 0.04 ± 0.00 0.08 ± 0.00* 0.06 ± 0.00*
#
 
LW/TL (g/cm) 0.42 ± 0.02 0.41 ± 0.01 0.72 ± 0.04* 0.69 ± 0.02* 
LiW/TL (g/cm) 2.97 ± 0.09 2.91 ± 0.10 2.90 ± 0.19 2.69 ± 0.07 
GcW/TL (g/cm) 0.53 ± 0.02 0.52 ± 0.02 0.46 ± 0.01* 0.45 ± 0.02* 
Abbreviations: BW, body weight; GcW, gastrocnemius weight; HW, heart weight; LiW, liver weight; LV+SW, left ventricle + septum 
weight; LW, lung weight; RVW, right ventricle weight; TL, tibia length. *p<0.05 vs CTRL, #p<0.05 vs MCT. CTRL (n=13); CTRL+UCN-2 
(n=10); MCT (n=10) and MCT+UCN-2 (n=15). 
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FIGURE 6. Histological analysis of cardiomyocyte structure and cross sectional area (CSA). On the left is 
depicted representative light microscopy images of hematoxylin-eosin (HE) stained sections of RV (400x) 
from CTRL (A), CTRL+UCN-2 (B), MCT (C) and MCT+UCN-2 (D), showing augmented cardiomyocyte 
dimensions in MCT animals. On the right is displayed a diagram with the quantification of cardiomyocyte 
dimensions, in which MCT animals showed an increased cardiomyocyte CSA when compared to CTRL 
group. Treatment was able to attenuate cardiomyocyte alterations. CTRL (n=7); CTRL+UCN-2 (n=7); MCT 
(n=7) and MCT+UCN-2 (n=8). 
 
Molecular Studies 
mRNA Expression 
We found that in the RV of animals from the MCT group, UCN-2 mRNA levels were 
notably increased in relation to other study groups (MCT: 2.13 ± 0.81 AU). Moreover, it was 
found that chronic administration of UCN-2 in control animals did not induce significant 
changes in UCN-2 expression (CTRL vs CTRL+UCN-2: 1.00 ± 0.34 vs 0.51 ± 0.17 AU). In the RV of 
animals from the MCT+UCN-2 group, there was a normalization of the UCN-2 expression (0.23 
± 0.08 AU). CRHR2 mRNA expression was decreased in the RV of MCT group animals (0.46 ± 
0.08 AU) and also normalized in MCT+UCN-2 animals (0.87 ± 0.12 AU) (Figure 7). 
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FIGURE 7. mRNA quantification of UCN-2 and CRHR2 in the RV. MCT group showed increased expression 
of UCN-2 while MCT+UCN-2 group showed significantly lower levels of expression (left). Regarding 
CRHR2, the MCT group showed decreased expression of the receptor that was reversed with treatment 
(right). The diagrams represent mean±SEM of UCN-2 and CRHR2 expression. AU stands for arbitrary 
units. CTRL (n=5); CTRL+UCN-2 (n=6); MCT (n=5) and MCT+UCN-2 (n=8). 
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Additionally, we determined the gene expression levels of ET-1 and BNP, markers of 
ventricular hypertrophy160 and cardiac overload161. In the RV of MCT animals we observed an 
increase in the mRNA expression of ET-1 (MCT vs CTRL: 3.39 ± 0.37 vs 1.00 ± 0.18 AU) and BNP 
(15.29 ± 2.50 vs 1.00 ± 0.10 AU). Hypoxia-inducible factor 1 alpha (HIF-1α) regulates the 
transcription of genes involved in adaptive responses to hypoxia162 and its expression was also 
elevated in the MCT group (1.61 ± 0.30 vs 1.00 ± 0.16 AU). ET-1 and HIF-1α expressions were 
reversed with UCN-2 treatment (MCT+UCN-2: 1.84 ± 0.57 and 1.01 ± 0.15 AU, respectively) 
while BNP expression was attenuated by 7-fold (6.92 ± 2.14 AU) as shown in Figure 8. 
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FIGURE 8. mRNA quantification of ET-1, BNP and HIF-1α in the RV. MCT group showed increased 
expression of ET-1, BNP and HIF-1α. UCN-2 chronic treatment attenuated BNP and reversed ET-1 and 
HIF-1α expressions. The diagrams represent mean±SEM of ET-1, BNP and HIF-1α expressions. AU stands 
for arbitrary units. CTRL (n=5); CTRL+UCN-2 (n=6); MCT (n=5) and MCT+UCN-2 (n=8). 
 
UCN-2, as described above, has been associated with signaling pathways of cell survival. 
In this context we analyzed caspase-3 and caspase-8. In apoptosis-associated genes, both 
caspase-3 and -8 were altered with increased levels in MCT animals (MCT vs CTRL: caspase-3, 
3.90 ± 0.59 vs 1.00 ± 0.13 AU and caspase-8, 2.81 ± 0.35 vs 1.00 ± 0.16 AU). Attenuation of 
caspase-3 (MCT+UCN-2: 2.02 ± 0.38 AU) and normalization of caspase-8 expression (1.34 ± 
0.21 AU) was seen with UCN-2 treatment (Figure 9). 
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FIGURE 9. mRNA quantification of caspase-3 and caspase-8 in the RV. Both caspases were decreased in 
MCT group, while UCN-2 treatment was able to reverse caspase-8 and attenuate caspase-3 expression. 
The diagrams represent mean±SEM of caspase-3 and -8 expressions. AU stands for arbitrary units. CTRL 
(n=5); CTRL+UCN-2 (n=6); MCT (n=5) and MCT+UCN-2 (n=8). 
 
Protein Expression 
CRHR2, a membrane-bound protein that belongs to the family of GPCRs, is the 
endogenous receptor with greater affinity for UCN-2 binding107. The expression of this receptor 
was particularly high in both MCT groups (MCT: 3.07 ± 0.67 and MCT+UCN-2: 3.34 ± 0.83 AU) 
when compared to CTRL group (1.00 ± 0.14 AU) (Figure 10). 
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FIGURE 10. Level of CRHR2 expression in the RV. CRHR2 expression was higher in MCT groups. The 
presence of CRHR2 was detected by immunoblotting utilizing total protein-specific primary antibodies. 
The diagrams represent mean±SEM of CRHR2 bands. The CRHR2 bands were normalized to GAPDH 
bands. Below the diagrams is depicted the representative western blot bands. AU stands for arbitrary 
units. CTRL (n=9); CTRL+UCN-2 (n=9); MCT (n=7) and MCT+UCN-2 (n=10). 
 
 
ERK1/2 or p44/42 and p38 belong to the MAPK family and are activated in response to a 
wide range of extracellular stimuli including mitogens, growth factors and cytokines163. In MCT 
animals we observed a decrease in protein phosphorylation/activation of both ERKs and p38 
kinases comparatively to controls (MCT vs CTRL: ERKs, 0.53 ± 0.10 vs 1.00 ± 0.11 AU and p38, 
0.52 ± 0.04 vs 1.00 ± 0.14 AU). These levels were reversed with UCN-2 treatment (MCT+UCN-2: 
ERKs, 0.92 ± 0.11 AU and p38, 1.14 ± 0.17) (Figure 11). 
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FIGURE 11. Activation level of ERKs and p38 in the RV. Both ERKs and p38 (left to right) activation was 
decreased in MCT animals and UCN-2 treatment was able to reverse their activation to control values. 
Phosphorylation was determined by immunoblotting utilizing total protein- and phosphorylation-
specific primary antibodies. The diagrams represent mean±SEM of ERKs and p38 bands. Below is 
depicted the respective representative western blot bands. Phospho-ERKs and –p38 are denoted as p-
ERKs and p-p38. AU stands for arbitrary units. CTRL (n=9); CTRL+UCN-2 (n=9); MCT (n=7) and MCT+UCN-
2 (n=10). 
 
Akt is a kinase known by its central regulatory role in several cellular processes such as 
cell survival and proliferation, glucose metabolism and cardiovascular homeostasis164. Akt 
activation did not show any significant differences between groups. UCN-2 treatment did not 
induce any difference in the phosphorylation level of Akt (Figure 12). 
 
C T R L M C T
0 .0
0 .5
1 .0
1 .5
2 .0
p
-A
k
t/
A
k
t 
(A
U
)
V e h ic le
U C N -2
                        
FIGURE 12. Activation level of Akt in the RV. Akt activation (on the left) did not show any difference 
between groups. Phosphorylation was determined by immunoblotting utilizing total protein- and 
phosphorylation-specific primary antibodies. The diagrams represent mean±SEM of Akt bands. Below is 
depicted the respective representative western blot bands. Phospho-Akt is denoted as p-Akt. AU stands 
for arbitrary units. CTRL (n=9); CTRL+UCN-2 (n=9); MCT (n=7) and MCT+UCN-2 (n=10). 
 
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an 
important signaling molecule for several cytokines and growth factor receptors, known for 
possessing an oncogenic potential and anti-apoptotic activities165. The MCT group showed a 
decreased STAT3 phosphorylation when compared with the CTRL group (MCT vs CTRL: 0.61 ± 
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0.12 vs 1.00 ± 0.10 AU). Treatment with UCN-2 resulted in restored STAT3 activation 
(MCT+UCN-2: 1.01 ± 0.09 AU) as we can see in Figure 13. 
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FIGURE 13. Activation level of STAT3 in the RV. STAT3 activation was decreased in MCT animals and UCN-
2 treatment was able to reverse its reduction. Phosphorylation was determined by immunoblotting 
utilizing total protein- and phosphorylation-specific primary antibodies. The diagrams represent 
mean±SEM of STAT3 bands. Below the diagrams is depicted the representative western blot bands. 
Phospho-STAT3 is denoted as p-STAT3 and AU stands for arbitrary units. CTRL (n=9); CTRL+UCN-2 (n=9); 
MCT (n=7) and MCT+UCN-2 (n=10). 
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UCN-2 treatment improves survival and RV function in MCT-induced PAH 
This study demonstrated that the chronic treatment with UCN-2 in an experimental 
model of PAH and secondary RV failure, attenuates structural remodeling and enhances RV 
systolic and diastolic function. 
Several studies166-168 have demonstrated the progression of MCT-induced PAH using 
echo-measured indexes of RV function and structure, proving the importance of non-invasive 
methods in the evaluation of PAH severity and RV function, since it allows a comparable 
approach to that routinely used in patients62. 
In MCT-induced PAH we observed a decrease in PAAT and PAET, which significantly 
altered the PAAT/PAET ratio, and in systolic flow which is compromised in PAH, is associated 
with pulmonary systolic pressures169 and correlates with decreased survival in PAH patients62. 
Pulmonary flow velocity, acceleration and ejection time were also restored with UCN-2 
pharmacological intervention, revealing an improved pulmonary arterial function and 
decreased RV afterload. 
Accordingly to previous studies167, 168 we observed a significant RV and right atria 
chamber dilation, shown by the echo-measured RV and RAA. At this time point (4th week after 
MCT injection) and with a progressive increase in PVR, the RV cannot sustain the adaptive 
hypertrophy and eventually dilates51. This was shown by Hardziyenka et al. that measured 
RVEDD echocardiographycally and showed that it seems to start to increase between 20-25 
days post MCT administration. Furthermore, in response to progressive pressure overload 
there is a shift of the IVS to the left side chamber170, which is in agreement with our 
observations (Figure 4B). Moreover, echo-measured TAPSE, an indicator of RV contractile 
function170, was also decreased in MCT animals. UCN-2 therapeutic intervention attenuated 
the adaptive hypertrophy and improved RV function and structure, as well as correcting IVS 
deviation. CO and CI, indexes of overall cardiac function, were also altered in MCT animals and 
were normalized with UCN-2 treatment. 
Although no studies have invasively evaluated UCN-2’s chronic treatment effect on RV 
function in PAH, enough studies have been performed on the LV that allows us to explain our 
results. Those studies showed improved cardiac performance in models of HF subjected to 
UCN-2 intervention. Bale et al. studied the acute effects of UCN-2 in a murine model of HF and 
although LVEDP was not different between wild-type and CRHR2-deficient mice, they noticed 
an increase in HR, EF and CO, as well as a decrease in LVEDV and ESV129. In anaesthetized pigs, 
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intracoronary infusion of UCN-2 caused an increase in coronary blood flow and CO, 
accompanied by a decrease in coronary vascular resistances89. 
Recently, both humans with mild HF149 and acute decompensated HF91 were subjected 
to UCN-2 administration. In the latter, UCN-2 treatment was able to decrease systolic blood 
pressure and increase CO, associated with a strong reduction in total peripheral resistance. 
Administration of UCN-2 in humans with mild HF increased CO and LVEF and decreased mean 
arterial pressure, systemic vascular resistance and cardiac work, in a dose-dependent manner. 
In both studies UCN-2 was able to induce vasodilation and improve myocardial function. 
Similarly, and despite all the structural differences between the LV and the RV, our 
functional RV study match what has been previously described for the LV. MCT-injected 
animals revealed a severe cardiac dysfunction secondary to PAH and presented RV 
hypercontractility, as shown by highly increased systolic pressures, as well by changes in other 
parameters of contractile function, namely IVC occlusion-derived ESPV relationship’s slope. 
Diastolic dysfunction was also present in the RV of MCT animals, shown by increased stiffness 
(rise in RVEDP) and RV dilation (increased RVEDD). These hemodynamic alterations correspond 
to decompensated myocardial hypertrophy of the RV in response to pressure overload 
resulting from increased pulmonary vascular resistance, as previously described 171. 
Treating MCT animals with UCN-2 resulted in the improvement of RV function, given 
that both systolic and diastolic dysfunction was enhanced and the ventricle showed improved 
contractile and relaxation functions. Cardiac catheterization allowed a more detailed analysis 
of ventricular function and corroborated echocardiographic data, nevertheless some caution is 
needed when interpreting the results and extrapolating previous knowledge from the LV to 
explain RV pathophysiology172. 
 
MCT-induced RV morphohistological changes are attenuated with UCN-2 treatment 
UCN-2 treatment after PAH-induction resulted in accentuated decrease of cardiac 
hypertrophy, especially RV hypertrophy (Table 11). HW was increased in PAH animals, as 
previously mentioned, and this was analyzed using the HW/BW ratio. Nevertheless, in PAH, the 
RV is the primary affected ventricle and therefore should be the focus of the analysis, since 
due to the augmented PVR is under pressure overload. And in fact, the RVW/BW ratio was also 
increased in PAH animals, which revealed the presence of RV hypertrophy. 
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Despite being in agreement with all of our data regarding hypertrophy and hypertrophy-
associated parameters measured, the model we’re using is associated with cachexia158 and 
because of that, we alternatively measured the RVW/TL ratio which is accepted as a reliable 
parameter for hypertrophy measurement159. The RVW/LV+SW ratio was consistent with the 
previously mentioned measurements. Lung edema and congestion is a consequence of PAH173 
and using the LW/TL ratio we observed an increase ratio in the MCT group, suggestive of PAH-
associated lung fluid retention. 
At the cellular level, our model of PAH developed cardiomyocyte hypertrophy, as 
measured by cardiomyocyte CSA. These effects were however reverted by UCN-2 
administration. The reversal of hypertrophy in response to treatment underlines the functional 
recovery observed with non-invasive and invasive hemodynamic measurements. The RV of 
treated animals is under attenuated pressure overload and therefore its adaptive hypertrophic 
response is decreased. Less muscle mass, less developed force and consequently, attenuated 
developed pressures and hypercontractile state. 
 
Expression of the UCN-2/CRHR2 in PAH and alterations with UCN-2 treatment 
Given that the used animal model of PAH is characterized by several structural and 
functional cardiac abnormalities over time, expressed by compensated RV hypertrophy at 2-3 
weeks and RH failure after 3-5 weeks170, 174 it seems relevant to search, between experimental 
groups, for possible differences in the expression of UCN-2 and its receptor, as well as the 
expression of genes encoding regulatory proteins relevant for ventricular contractile function. 
Moreover, these studies allowed us a better characterization of the variations occurring in the 
UCN-2/CRHR2 system and downstream signaling in the context of PAH and progression to HF, 
which can provide us an explanation for the alterations detected in the functional studies. 
UCN-2 and its receptor, CRHR2, have been implicated in several cardiovascular 
diseases91, 141, 149, 175. In spontaneously hypertensive rats, Nishikimi et al. described a higher 
UCN mRNA expression in hypertrophied LV than in normal LV, whereas CRHR2 expression was 
depressed103. Moreover, Emeto et al. demonstrated augmented expression of UCN-2 in 
biopsies from abdominal aortic aneurysm (AAA) and despite not being cardiac tissue, the same 
study also showed increased levels of UCN-2 in plasma samples of AAA patients, which are 
associated with this cardiovascular disorder141. Additionally, other group analyzed and 
compared the prognostic efficacy of both plasma UCN and NT-proBNP levels in acute 
myocardial infarction and correlated the high plasmatic UCN levels with increased mortality176. 
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In our study we also observed increased levels of UCN-2 mRNA expression and a sharp 
fall in the mRNA expression of the CRHR2 which complies with the studies cited above. In 
addition, UCN-2 levels also seem to correlate with increased morbidity and mortality176, 
despite its beneficial effects. In our study, the decreased levels of CRHR2 expression may be 
related with the increased UCN-2 expression in the RV, wherein by a mechanism of negative 
feedback, UCN-2 regulates CRHR2 mRNA expression. UCN-2 treatment was able to reduce 
UCN-2 endogenous expression and augment CRHR2 expression, normalizing both expressions 
to control levels. 
Taken together, these results suggest that increased UCN-2 in the RV from MCT animals 
may be associated with an adaptive process of the cardiac muscle. In consequence, one can 
predict that UCN-2 may play an important role in the pathophysiology of PAH and progression 
to HF. 
 
Increased expression of cardiac overload, hypertrophy and hypoxia markers in PAH was 
attenuated with UCN-2 treatment 
Neurohumoral activation is associated with RV dysfunction in PAH177 and growing 
evidences show that UCN-2 modulates the gene expression and/or the activity of several 
neurohumoral agents, such as ET-1 and BNP, involved in PAH and progression to HF90, 143. 
ET-1 plasmatic levels are elevated in PAH and are associated with disease severity27. In 
addition, its clearance from pulmonary arteries is reduced, promoting further 
vasoconstriction179. ET-1 levels are associated with the development of RV hypertrophy in 
MCT-induced PAH180 and its RV expression is increased in this experimental model181. 
Plasmatic BNP levels are associated with PH182 and increased in MCT-injected rats181. The 
production of BNP is stimulated in response to pressure-overload183 and is associated with the 
extent of RV dysfunction184. Moreover, NT-proBNP along with UCN-2 plasmatic levels holds an 
enhanced prognostic value, since their levels correlate with increased mortality, as previously 
cited176. 
In our study, both ET-1 and BNP mRNA expressions were augmented in PAH animals up 
to 3-fold and 15-fold, respectively. While UCN-2 treatment was able to attenuate ET-1 to 2-fold 
and BNP to 7-fold, in accordance with previous studies143, 178. 
Hypoxia-inducible factor 1 alpha (HIF-1α) is a heterodimeric subunit of the transcription 
factor HIF-1, which regulates the transcription of genes involved in adaptive responses to 
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hypoxia162. Chu et al. showed that HIF-1α overexpression promotes the development of 
cardiac hypertrophy via up-regulation of Ca+2-calcineurin under mild hypoxia conditions185. 
However, increased [Ca2+]i is not only associated with hypertrophy but also with apoptotic 
processes under severe hypoxia situation, given that some reports showed that HIF-1α 
overexpression promotes apoptosis of cardiac myocytes in the presence of severe hypoxia, 
especially when other cellular energy substrates are lacking186. In our study, RV HIF-1α 
expression was also increased in MCT animals and UCN-2 treatment was able to reverse HIF-
1α expression to control levels. The identification of a binding region for HIF-1α in human UCN-
2 gene that regulates transcription in response to hypoxia, explains why both levels of UCN-2 
and HIF-1α correlate. Buhler et al. proposed that the induction of hUCN-2 expression by low 
oxygen levels may confer to cardiac myocytes an advantage in ischemic conditions187. 
 
UCN-2 treatment reverses changes in markers of apoptosis in PAH 
Apoptosis is one of the major mechanisms causing cardiomyocyte loss in failing hearts of 
both human patients188 and animal models189. In turn, UCN-2 appears to have cardioprotective 
effects by preventing cardiomyocyte death175, 190, 191. 
Upon cleavage, caspase-3 is activated in the myocardium of end-stage HF patients192 
being also involved in the development of pressure overload-induced LV dysfunction, as well 
as hyperglycemia-induced myocardial apoptosis193. Studies that used the MCT-induced PAH 
model showed increased caspase-3 activation in those animals194, 195 and in myocardial 
infarction, the overexpression of this enzyme induced myofibrillar ultrastructural damage and 
when subjected to myocardial ischemia-reperfusion (I/R) injury, caspase-3 transgenic mice 
showed increased infarct size and a pronounced susceptibility to die196.  
Caspase-8, a cysteine protease, has the ability to activate downstream caspases, 
including caspase-3, and therefore it is critically involved in the regulation of cellular apoptosis, 
as well as necrotic cell death197. In human cardiomyocytes, iron-induced apoptosis was linked 
to increased levels of caspase-8198. In a mouse model of HF, the inhibition of Fas-associated 
death domain-containing protein (FADD) had a protective role in myocardial I/R injury and was 
correlated with increased caspase-8 activity and downstream caspase-3 activity197. 
In our study, the high detected mRNA levels of both caspase-3 and caspase-8 in the RV 
of the MCT rats were reverted by UCN-2 treatment which is consistent with other studies134, 199 
and confirms the hypothesis that UCN-2/CRHR2 system has anti-apoptotic proprieties. 
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UCN-2 treatment normalized the alterations in some elements of the UCN-2/CRHR2 signaling 
pathway seen in MCT animals 
In rats, the administration of MCT usually leads to cardiac hypertrophy that develops 
due to increasing oxidants, hemodynamic load and by inducing hypoxia. The mechanisms that 
lead to cardiac hypertrophy  and progression to HF involve the activation G-proteins, calcium 
signaling, PI3K, PKCs and MAPKs200. In this study one of our goals was to find which signaling 
pathways are deregulated in MCT-induced PAH animals and which are involved in UCN-2 
beneficial effects. 
ERK1/2 or p44/42 and p38 belong to the MAPK family and are activated in response to a 
wide range of extracellular stimuli including mitogens, growth factors and cytokines. When 
activated, they have the ability to regulate other kinases and several transcription factors163. 
Defects downstream of BMP signaling pathway, involving p38 and ERKs, have been linked to 
PAH201 and increased activation of ERK1/2 and p38 was found in lung tissue of MCT-induced 
PH model, while a suppression of this activation was observed with treatment202. 
On the other hand and for the first time, Kehat and Molkentin proposed that eccentric 
hypertrophy is induced by de-activation of the ERK pathway203 and Bartelds et al. confirmed it 
by observing a decrease in phosphorylated ERK1/2 in mice subjected to volume and pressure 
overload204. Furthermore, in a model of transverse aortic constriction (TAC) that resulted in 
late eccentric hypertrophy with eventual development of LV dysfunction, implicated the 
importance of ERK1/2 downregulation and enhanced cardiomyocyte apoptosis in the 
transition from compensated hypertrophy to HF205. 
In relation to p38, Pérez López et al. showed that the disruption of the AKAP/p38 
signaling complex inhibits compensatory hypertrophy in response to aortic banding-induced 
pressure overload and promotes early cardiac dysfunction associated with increased 
myocardial apoptosis and ventricular dilation206. 
In consequence, our decreased phosphorylation of both kinases in the RV of MCT 
animal’s is in accordance with previous studies, once at the time of sample collection, the MCT 
animals already showed an advanced stage of HF with evident RV dilation. In addition, the 
reversal of both kinases to its control levels comply with prior studies that showed a boost in 
the activation of both ERK 1/288 and p38 MAPK125, at this stage, upon UCN-2-binding to CRHR2, 
which accordingly to Bartelds et al. could be a mechanism to prevent the pressure-loaded RV 
from dilation204. 
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Akt or PKB is a serine/threonine kinase known by its critical and central regulatory role 
in several cellular processes such as cell survival and proliferation, glucose metabolism and 
cardiovascular homeostasis164. Akt is also a critical downstream element of the PI3K/Akt cell 
survival pathway, whose activity can be inhibited by Akt-mediated phosphorylation164. The 
PI3K/Akt pathway is also known to be activated by UCN-2116 and it’s particularly important in 
cardiac and skeletal muscle since it helps regulate PLB phosphorylation, along with PKA, 
controlling the inhibition of SERCA118. 
Although Akt was not significantly affected by any of the administered drugs (MCT and 
UCN-2) in resemblance with other studies202, 207. 
STAT3 is a transcription factor and an important signaling molecule for several cytokines 
and growth factor receptors, known for possessing an oncogenic potential and anti-apoptotic 
activities165. In myeloma tumor cells, the blocking of Jak-STAT pathway induces apoptosis, 
demonstrating that STAT3 signaling is essential for the survival of this type of cells
208. 
Akin to cancer, PAH is characterized by an imbalance between a proliferative and an 
apoptotic phenotype16. In PASMC proliferation is enhanced due to the activation of pro-
survival transcription factors, such as STAT3
209. And in fact, Courboulin et al. demonstrated that 
STAT3 phosphorylation was increased in PAH-PASMCs and that treatment with a STAT3 blocker 
reversed this state. 
However, in the cardiac tissue the opposite happens. Because the RV is not able to 
sustain long-term pressure overload, the cardiac contractile force decreases due to apoptosis 
and changes in cardiomyocytes, and eventually the RV dilates51. Following this notion, Chen-
Scarabelli et al. verified that cardiac cells incubated with UCN showed increased STAT3 
phosphorylation at Tyr705. Moreover, overexpression of STAT3 in cardiac myocytes pretreated 
with UCN presented a reduced magnitude of cell death, when compared with UCN treatment 
alone. While transfection of cells with a mutant STAT3 (loss of function) enhanced the extent of 
cell death in a dose-dependent manner210. 
Hereupon, the increased STAT3 phosphorylation in the RV of the MCT treated animal’s 
match what has been previously described for the cardiomyocytes, demonstrating the 
cardioprotective effect and anti-apoptotic proprieties of UCN-2. 
The increased expression of CRHR2 in the RV of MCT animals, obtained by western blot 
analysis, contrarily to its mRNA expression, may be related with our decreased activation of 
ERK1/2, since according to Markovic et al., the endocytosis of CRHR2 appears to be regulated 
by ERK1/2 direct phosphorylation of β-arrestin1 in an auto-regulatory mechanism that 
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influences the rate and extent of β-arrestin1 recruitment to the plasma membrane and 
interaction with CRHR2
112. Thus, the elevated presence of CRHR2 in the RV from MCT animals 
could be associated with the deregulation seen in the pathway that leads to receptor 
internalization and degradation. 
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In short, we show for the first time, in an experimental model of MCT-induced PAH, that 
UCN-2 treatment is able to restore PAH-induced severe abnormalities in cardiac function and 
structure, while attenuating or reversing the expression of markers of cardiac overload, 
hypertrophy, hypoxia and apoptosis. We also demonstrated that the UCN-2 beneficial effects 
are associated and involve the modulation of several signaling pathways downstream CRHR2 
activation. 
PAH is a chronic syndrome that is frequently diagnosed in a later stage, where HF is 
already settled. Therefore our approach adds the benefit of a more practical and clinical 
relevant therapy, since we begin the treatment after PAH was established.  
The UCN-2 and its receptor have been studied in the cardiovascular system, but 
research so far has failed to determine its effects on both normal and diseased RV physiology. 
With this study, we demonstrated the effects of an increase in UCN-2 levels through 
exogenous administration of the peptide, which has shown that specific activation of CRHR2 
mediates several compensatory mechanisms that ameliorate the dysfunction and structural 
abnormalities associated with PAH and RVF. 
However, it is also important to take into account that the animal model used in the 
present study does not mimic entirety human PH or PAH, nevertheless it has several 
pathophysiological alterations in common that allow us to enthusiastically point UCN-2 as a 
possible novel therapeutic approach for this incurable and with an uncertain prognosis 
disease. 
In fact, we hope to have opened the road for further basic and translational research 
that could possibly lead to the establishment of UCN-2 as a novel and safe therapeutic agent 
for treating patients with PAH and RVF. 
In spite of these results, further research is needed in order to determine specifically 
where UCN-2 plays its major role. The ventricular function is altered, but since in this model RV 
dysfunction and HF is secondary to PAH, we cannot ascertain whether RV function and 
structure improvement is secondary to pulmonary vascular functional enhancement and 
therefore decreased vascular resistances, or if UCN-2 has a direct effect on the ventricle which 
by itself is capable of leading to the changes we observed. In the future, in order to 
differentiate indirect from direct myocardial effects of UCN-2 treatment, we predict the use of 
an animal model of RV overload. 
Beyond RV function and structure, we intent do access pulmonary function and 
structure as well, by in vitro (vascular ring preparations) and histological studies. Moreover, 
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our molecular results here described will allow us to design and perform further studies in 
order to unravel more signaling pathways underlying the beneficial effects of UCN-2/CRHR2 
system activation in PAH and RV HF, in both RV and lung samples. 
  
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 74  
 
1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, 
Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. 
Accf/aha 2009 expert consensus document on pulmonary hypertension a 
report of the american college of cardiology foundation task force on expert 
consensus documents and the american heart association developed in 
collaboration with the american college of chest physicians; american thoracic 
society, inc.; and the pulmonary hypertension association. J Am Coll Cardiol. 
2009;53:1573-1619 
2. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, 
Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions 
and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42-50 
3. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti 
M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, 
Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the 
diagnosis and treatment of pulmonary hypertension: The task force for the 
diagnosis and treatment of pulmonary hypertension of the european society of 
cardiology (esc) and the european respiratory society (ers), endorsed by the 
international society of heart and lung transplantation (ishlt). Eur Heart J. 
2009;30:2493-2537 
4. Hatano S ST. Primary pulmonary hypertension. 1975 
5. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs 
S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of 
pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S-12S 
6. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, 
Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, 
Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll 
Cardiol. 2009;54:S43-54 
7. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, 
Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski 
H, Robbins IM, Souza R. Updated clinical classification of pulmonary 
hypertension. J Am Coll Cardiol. 2013;62:D34-41 
8. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, 
Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial 
hypertension in carriers of bmpr2 mutation. American journal of respiratory 
and critical care medicine. 2008;177:1377-1383 
9. Humbert M, Montani D, Evgenov OV, Simonneau G. Definition and 
classification of pulmonary hypertension. Handbook of experimental 
pharmacology. 2013;218:3-29 
10. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, 
Tuder RM. Pathologic assessment of vasculopathies in pulmonary 
hypertension. J Am Coll Cardiol. 2004;43:25S-32S 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 75  
 
11. Montani D, Gunther S, Dorfmuller P, Perros F, Girerd B, Garcia G, Jais X, Savale 
L, Artaud-Macari E, Price LC, Humbert M, Simonneau G, Sitbon O. Pulmonary 
arterial hypertension. Orphanet journal of rare diseases. 2013;8:97 
12. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of 
plexiform lesions in pulmonary hypertension associated with scleroderma and 
human immunodeficiency virus infection. Human pathology. 1997;28:434-442 
13. Bjornsson J, Edwards WD. Primary pulmonary hypertension: A histopathologic 
study of 80 cases. Mayo Clinic proceedings. 1985;60:16-25 
14. Dorfmuller P. Pulmonary hypertension: Pathology. Handbook of experimental 
pharmacology. 2013;218:59-75 
15. Waxman AB, Zamanian RT. Pulmonary arterial hypertension: New insights into 
the optimal role of current and emerging prostacyclin therapies. The American 
journal of cardiology. 2013;111:1A-16A; quiz 17A-19A 
16. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, 
Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and 
molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 
2004;43:13S-24S 
17. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular 
remodeling in pulmonary hypertension. Progress in cardiovascular diseases. 
2002;45:173-202 
18. Davie NJ, Crossno JT, Jr., Frid MG, Hofmeister SE, Reeves JT, Hyde DM, 
Carpenter TC, Brunetti JA, McNiece IK, Stenmark KR. Hypoxia-induced 
pulmonary artery adventitial remodeling and neovascularization: Contribution 
of progenitor cells. American journal of physiology. Lung cellular and molecular 
physiology. 2004;286:L668-678 
19. Jonigk D, Golpon H, Bockmeyer CL, Maegel L, Hoeper MM, Gottlieb J, Nickel N, 
Hussein K, Maus U, Lehmann U, Janciauskiene S, Welte T, Haverich A, Rische J, 
Kreipe H, Laenger F. Plexiform lesions in pulmonary arterial hypertension 
composition, architecture, and microenvironment. The American journal of 
pathology. 2011;179:167-179 
20. Kherbeck N, Tamby MC, Bussone G, Dib H, Perros F, Humbert M, Mouthon L. 
The role of inflammation and autoimmunity in the pathophysiology of 
pulmonary arterial hypertension. Clinical reviews in allergy & immunology. 
2013;44:31-38 
21. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, 
Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and 
molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 
2009;54:S20-31 
22. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau 
G. Pathobiology of pulmonary hypertension. The role of platelets and 
thrombosis. Clinics in chest medicine. 2001;22:451-458 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 76  
 
23. Montani D, Chaumais MC, Guignabert C, Gunther S, Girerd B, Jais X, 
Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M. 
Targeted therapies in pulmonary arterial hypertension. Pharmacology & 
therapeutics. 2014;141:172-191 
24. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, 
Voelkel NF. Prostacyclin synthase expression is decreased in lungs from 
patients with severe pulmonary hypertension. American journal of respiratory 
and critical care medicine. 1999;159:1925-1932 
25. Maron BA, Loscalzo J. Pulmonary hypertension: Pathophysiology and signaling 
pathways. Handbook of experimental pharmacology. 2013;218:31-58 
26. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, 
Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of 
patients with pulmonary hypertension. The New England journal of medicine. 
1993;328:1732-1739 
27. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, 
Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated 
with the severity of primary pulmonary hypertension. Chest. 2001;120:1562-
1569 
28. Gangopahyay A, Oran M, Bauer EM, Wertz JW, Comhair SA, Erzurum SC, Bauer 
PM. Bone morphogenetic protein receptor ii is a novel mediator of endothelial 
nitric-oxide synthase activation. The Journal of biological chemistry. 
2011;286:33134-33140 
29. Butcher RW, Sutherland EW. Adenosine 3',5'-phosphate in biological materials. 
I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and 
use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. 
The Journal of biological chemistry. 1962;237:1244-1250 
30. Francis SH, Busch JL, Corbin JD, Sibley D. Cgmp-dependent protein kinases and 
cgmp phosphodiesterases in nitric oxide and cgmp action. Pharmacological 
reviews. 2010;62:525-563 
31. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, 
Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. 
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right 
ventricle, and acute inhibition of phosphodiesterase type 5 improves 
contractility. Circulation. 2007;116:238-248 
32. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, 
Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in 
human pulmonary artery cells. American journal of respiratory and critical care 
medicine. 2005;172:105-113 
33. Waxman AB. Pulmonary hypertension in heart failure with preserved ejection 
fraction: A target for therapy? Circulation. 2011;124:133-135 
34. Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Toshner M, 
Sheares KK, Pepke-Zaba J. Acute haemodynamic responses to inhaled nitric 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 77  
 
oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary 
hypertension (cteph). Vascular pharmacology. 2007;46:449-455 
35. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. 
Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit 
potassium current in rat pulmonary vascular smooth muscle and cause 
pulmonary vasoconstriction. Circulation. 1996;94:2216-2220 
36. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV, Jr., Gaine SP, Orens JB, 
Rubin LJ. Dysfunctional voltage-gated k+ channels in pulmonary artery smooth 
muscle cells of patients with primary pulmonary hypertension. Circulation. 
1998;98:1400-1406 
37. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the 
pulmonary circulation: Receptors, transporters and relevance to pulmonary 
arterial hypertension. British journal of pharmacology. 2000;131:161-168 
38. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, 
Poubeau P, Cerrina J, Duroux P, Drouet L. Increased plasma serotonin in 
primary pulmonary hypertension. The American journal of medicine. 
1995;99:249-254 
39. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guerin P, Sagan C, Pacaud P, Loirand 
G. Inhibition of rhoa/rho kinase pathway is involved in the beneficial effect of 
sildenafil on pulmonary hypertension. British journal of pharmacology. 
2005;146:1010-1018 
40. Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert 
M, Fadel E, Adnot S, Loirand G, Pacaud P. Rhoa and rho kinase activation in 
human pulmonary hypertension: Role of 5-ht signaling. American journal of 
respiratory and critical care medicine. 2009;179:1151-1158 
41. Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: 
Clinical patterns. The American review of respiratory disease. 1984;129:194-197 
42. Cogan JD, Pauciulo MW, Batchman AP, Prince MA, Robbins IM, Hedges LK, 
Stanton KC, Wheeler LA, Phillips JA, 3rd, Loyd JE, Nichols WC. High frequency of 
bmpr2 exonic deletions/duplications in familial pulmonary arterial 
hypertension. American journal of respiratory and critical care medicine. 
2006;174:590-598 
43. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, 
Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, 
Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial 
hypertension in france: Results from a national registry. American journal of 
respiratory and critical care medicine. 2006;173:1023-1030 
44. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig 
E, Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, 
Glissmeyer E, Carlquist J, Kim M, Torbicki A, Fijalkowska A, Szewczyk G, Parma J, 
Abramowicz MJ, Galie N, Morisaki H, Kyotani S, Nakanishi N, Morisaki T, 
Humbert M, Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell NW, 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 78  
 
Trembath RC. Mutations of the tgf-beta type ii receptor bmpr2 in pulmonary 
arterial hypertension. Human mutation. 2006;27:121-132 
45. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, Tregouet D, Reis A, 
Drouin-Garraud V, Fraisse A, Sitbon O, O'Callaghan DS, Simonneau G, Soubrier 
F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in patients 
carrying an acvrl1 (alk1) mutation. American journal of respiratory and critical 
care medicine. 2010;181:851-861 
46. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott 
CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Halme M, 
Raisanen-Sokolowski A, Laitinen T, Morrell NW, Trembath RC. Molecular and 
functional analysis identifies alk-1 as the predominant cause of pulmonary 
hypertension related to hereditary haemorrhagic telangiectasia. Journal of 
medical genetics. 2003;40:865-871 
47. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, Bradshaw 
TY, Southgate L, Lee GJ, Jackson I, Lord GM, Gibbs JS, Wilkins MR, Ohta-Ogo K, 
Nakamura K, Girerd B, Coulet F, Soubrier F, Humbert M, Morrell NW, Trembath 
RC, Machado RD. Molecular genetic characterization of smad signaling 
molecules in pulmonary arterial hypertension. Human mutation. 2011;32:1385-
1389 
48. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath 
RC. Altered growth responses of pulmonary artery smooth muscle cells from 
patients with primary pulmonary hypertension to transforming growth factor-
beta(1) and bone morphogenetic proteins. Circulation. 2001;104:790-795 
49. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. 
Coronary artery disease. 2005;16:13-18 
50. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary 
arterial hypertension. European respiratory review : an official journal of the 
European Respiratory Society. 2011;20:243-253 
51. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under 
pressure: Cellular and molecular mechanisms of right-heart failure in 
pulmonary hypertension. Chest. 2009;135:794-804 
52. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno 
K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin 
JD, Zou Y, Komuro I. P53-induced inhibition of hif-1 causes cardiac dysfunction 
during pressure overload. Nature. 2007;446:444-448 
53. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased 
sympathetic nerve activity in pulmonary artery hypertension. Circulation. 
2004;110:1308-1312 
54. Gan C, Lankhaar JW, Marcus JT, Westerhof N, Marques KM, Bronzwaer JG, 
Boonstra A, Postmus PE, Vonk-Noordegraaf A. Impaired left ventricular filling 
due to right-to-left ventricular interaction in patients with pulmonary arterial 
hypertension. American journal of physiology. Heart and circulatory physiology. 
2006;290:H1528-1533 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 79  
 
55. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An 
epidemiological study of pulmonary arterial hypertension. The European 
respiratory journal. 2007;30:104-109 
56. Baptista R, Meireles J, Agapito A, Castro G, da Silva AM, Shiang T, Goncalves F, 
Robalo-Martins S, Nunes-Diogo A, Reis A. Pulmonary hypertension in portugal: 
First data from a nationwide registry. BioMed research international. 
2013;2013:489574 
57. McLaughlin VV. Survival in patients with pulmonary arterial hypertension 
treated with first-line bosentan. European journal of clinical investigation. 
2006;36 Suppl 3:10-15 
58. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, 
Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with 
primary pulmonary hypertension. Results from a national prospective registry. 
Annals of internal medicine. 1991;115:343-349 
59. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, 
Corretti MC, Hassoun PM. Accuracy of doppler echocardiography in the 
hemodynamic assessment of pulmonary hypertension. American journal of 
respiratory and critical care medicine. 2009;179:615-621 
60. Grignola JC. Hemodynamic assessment of pulmonary hypertension. World 
journal of cardiology. 2011;3:10-17 
61. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of 
calcium channel blockers in pulmonary arterial hypertension. Respiratory 
medicine. 2010;104:481-496 
62. Bossone E, D'Andrea A, D'Alto M, Citro R, Argiento P, Ferrara F, Cittadini A, 
Rubenfire M, Naeije R. Echocardiography in pulmonary arterial hypertension: 
From diagnosis to prognosis. Journal of the American Society of 
Echocardiography : official publication of the American Society of 
Echocardiography. 2013;26:1-14 
63. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB. 
Doppler echocardiographic index for assessment of global right ventricular 
function. Journal of the American Society of Echocardiography : official 
publication of the American Society of Echocardiography. 1996;9:838-847 
64. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, 
Chamera E, Corretti MC, Champion HC, Abraham TP, Girgis RE, Hassoun PM. 
Tricuspid annular displacement predicts survival in pulmonary hypertension. 
American journal of respiratory and critical care medicine. 2006;174:1034-1041 
65. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional 
and doppler-echocardiographic and cardiac catheterization correlates of 
survival in primary pulmonary hypertension. Circulation. 1989;80:353-360 
66. Ats statement: Guidelines for the six-minute walk test. American journal of 
respiratory and critical care medicine. 2002;166:111-117 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 80  
 
67. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, Wasserman K. 
Cardiopulmonary exercise testing and six-minute walk correlations in 
pulmonary arterial hypertension. The American journal of cardiology. 
2006;97:123-126 
68. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, 
Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain 
natriuretic peptide as a prognostic indicator in patients with primary pulmonary 
hypertension. Circulation. 2000;102:865-870 
69. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, Pruszczyk P, 
Burakowski J, Wawrzynska L. Detectable serum cardiac troponin t as a marker 
of poor prognosis among patients with chronic precapillary pulmonary 
hypertension. Circulation. 2003;108:844-848 
70. Nickel N, Kempf T, Tapken H, Tongers J, Laenger F, Lehmann U, Golpon H, 
Olsson K, Wilkins MR, Gibbs JS, Hoeper MM, Wollert KC. Growth differentiation 
factor-15 in idiopathic pulmonary arterial hypertension. American journal of 
respiratory and critical care medicine. 2008;178:534-541 
71. Lankeit M, Dellas C, Panzenbock A, Skoro-Sajer N, Bonderman D, Olschewski M, 
Schafer K, Puls M, Konstantinides S, Lang IM. Heart-type fatty acid-binding 
protein for risk assessment of chronic thromboembolic pulmonary 
hypertension. The European respiratory journal. 2008;31:1024-1029 
72. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent 
F, Herve P, Simonneau G. Long-term response to calcium channel blockers in 
idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111 
73. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, Humbert M, Simonneau 
G, Sitbon O. Long-term response to calcium-channel blockers in non-idiopathic 
pulmonary arterial hypertension. Eur Heart J. 2010;31:1898-1907 
74. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for 
pulmonary arterial hypertension. The Cochrane database of systematic reviews. 
2013;2:CD004434 
75. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, 
Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali 
S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW. A 
comparison of continuous intravenous epoprostenol (prostacyclin) with 
conventional therapy for primary pulmonary hypertension. The New England 
journal of medicine. 1996;334:296-301 
76. Dhillon S, Keating GM. Bosentan: A review of its use in the management of 
mildly symptomatic pulmonary arterial hypertension. American journal of 
cardiovascular drugs : drugs, devices, and other interventions. 2009;9:331-350 
77. Marsboom GRJ, S. P. Models for pulmonary hypertension. Drug Discovery 
Today: Disease Models. 2004;Vol. I, No. 3 
78. Schroll S, Arzt M, Sebah D, Nuchterlein M, Blumberg F, Pfeifer M. Improvement 
of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 81  
 
endothelin receptor antagonist bosentan. Respiratory physiology & 
neurobiology. 2010;170:32-36 
79. Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular 
endothelial growth factor attenuates monocrotaline-induced pulmonary 
hypertension. Circulation. 2001;104:2242-2248 
80. Sato K, Webb S, Tucker A, Rabinovitch M, O'Brien RF, McMurtry IF, Stelzner TJ. 
Factors influencing the idiopathic development of pulmonary hypertension in 
the fawn hooded rat. The American review of respiratory disease. 
1992;145:793-797 
81. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, 
Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice 
expressing a dominant-negative bmprii gene in smooth muscle. Circulation 
research. 2004;94:1109-1114 
82. Schnader J, Schloo BL, Anderson W, Stephenson LW, Fishman AP. Chronic 
pulmonary hypertension in sheep: Temporal progression of lesions. The Journal 
of surgical research. 1996;62:243-250 
83. Zagorski J, Debelak J, Gellar M, Watts JA, Kline JA. Chemokines accumulate in 
the lungs of rats with severe pulmonary embolism induced by polystyrene 
microspheres. J Immunol. 2003;171:5529-5536 
84. Pak OJ, W.; Ghofrani, H. A.; Seeger, W.;Grimminger, F.;Schermuly, R. T.; 
Weissmann, N. Animal models of pulmonary hypertension: Role in translational 
research. Drug Discovery Today: Disease Models. 2010;Vol. 7, No. 3-4 
85. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg 
FM. International union of pharmacology. Xxxvi. Current status of the 
nomenclature for receptors for corticotropin-releasing factor and their ligands. 
Pharmacological reviews. 2003;55:21-26 
86. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, 
Ebina M, Nukiwa T, Sasano H. Expression of urocortin and corticotropin-
releasing factor receptor subtypes in the human heart. The Journal of clinical 
endocrinology and metabolism. 2002;87:340-346 
87. Oki Y, Sasano H. Localization and physiological roles of urocortin. Peptides. 
2004;25:1745-1749 
88. Brar BK, Chen A, Perrin MH, Vale W. Specificity and regulation of extracellularly 
regulated kinase1/2 phosphorylation through corticotropin-releasing factor 
(crf) receptors 1 and 2beta by the crf/urocortin family of peptides. 
Endocrinology. 2004;145:1718-1729 
89. Grossini E, Molinari C, Mary DA, Marino P, Vacca G. The effect of urocortin ii 
administration on the coronary circulation and cardiac function in the 
anaesthetized pig is nitric-oxide-dependent. European journal of pharmacology. 
2008;578:242-248 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 82  
 
90. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated 
hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced 
sheep: Beneficial effects in heart failure. Circulation. 2005;112:3624-3632 
91. Chan WY, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 
infusion in acute decompensated heart failure: Findings from the unicorn study 
(urocortin-2 in the treatment of acute heart failure as an adjunct over 
conventional therapy). JACC. Heart failure. 2013;1:433-441 
92. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, 
Rademaker MT, Richards AM. Urocortin 2 infusion in healthy humans: 
Hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol. 
2007;49:461-471 
93. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, 
Turnbull AV, Lovejoy D, Rivier C, et al. Urocortin, a mammalian neuropeptide 
related to fish urotensin i and to corticotropin-releasing factor. Nature. 
1995;378:287-292 
94. Grace CR, Perrin MH, Cantle JP, Vale WW, Rivier JE, Riek R. Common and 
divergent structural features of a series of corticotropin releasing factor-related 
peptides. J Am Chem Soc. 2007;129:16102-16114 
95. Karteris E, Hillhouse EW, Grammatopoulos D. Urocortin ii is expressed in 
human pregnant myometrial cells and regulates myosin light chain 
phosphorylation: Potential role of the type-2 corticotropin-releasing hormone 
receptor in the control of myometrial contractility. Endocrinology. 
2004;145:890-900 
96. Vaughan JM, Donaldson CJ, Fischer WH, Perrin MH, Rivier JE, Sawchenko PE, 
Vale WW. Posttranslational processing of human and mouse urocortin 2: 
Characterization and bioactivity of gene products. Endocrinology. 
2013;154:1553-1564 
97. Liaw CW, Grigoriadis DE, Lorang MT, De Souza EB, Maki RA. Localization of 
agonist- and antagonist-binding domains of human corticotropin-releasing 
factor receptors. Mol Endocrinol. 1997;11:2048-2053 
98. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza 
EB, Oltersdorf T. Cloning and characterization of a functionally distinct 
corticotropin-releasing factor receptor subtype from rat brain. Proceedings of 
the National Academy of Sciences of the United States of America. 1995;92:836-
840 
99. Pal K, Swaminathan K, Xu HE, Pioszak AA. Structural basis for hormone 
recognition by the human crfr2{alpha} g protein-coupled receptor. The Journal 
of biological chemistry. 2010;285:40351-40361 
100. Wille S, Sydow S, Palchaudhuri MR, Spiess J, Dautzenberg FM. Identification of 
amino acids in the n-terminal domain of corticotropin-releasing factor receptor 
1 that are important determinants of high-affinity ligand binding. Journal of 
neurochemistry. 1999;72:388-395 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 83  
 
101. Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the 
regulation of the biological activity of corticotropin-releasing hormone 
receptors: Implications for physiology and pathophysiology. Endocrine reviews. 
2006;27:260-286 
102. Takahashi K, Totsune K, Murakami O, Saruta M, Nakabayashi M, Suzuki T, 
Sasano H, Shibahara S. Expression of urocortin iii/stresscopin in human heart 
and kidney. J Clin Endocrinol Metab. 2004;89:1897-1903 
103. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, 
Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropin-
releasing factor family, in normal and diseased heart. American journal of 
physiology. Heart and circulatory physiology. 2000;279:H3031-3039 
104. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls 
MG, Frampton CM, Richards AM. Urocortin-1 infusion in normal humans. The 
Journal of clinical endocrinology and metabolism. 2004;89:1402-1409 
105. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls 
MG, Frampton CM, Richards AM. Effect of urocortin 1 infusion in humans with 
stable congestive cardiac failure. Clin Sci (Lond). 2005;109:381-388 
106. Patel K, Rademaker MT, Kirkpatrick CM, Charles CJ, Fisher S, Yandle TG, 
Richards AM. Comparative pharmacokinetics and pharmacodynamics of 
urocortins 1, 2 and 3 in healthy sheep. British journal of pharmacology. 
2012;166:1916-1925 
107. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are 
selective ligands for the type 2 corticotropin-releasing hormone receptor. 
Nature medicine. 2001;7:605-611 
108. Rossant CJ, Pinnock RD, Hughes J, Hall MD, McNulty S. Corticotropin-releasing 
factor type 1 and type 2alpha receptors regulate phosphorylation of 
calcium/cyclic adenosine 3',5'-monophosphate response element-binding 
protein and activation of p42/p44 mitogen-activated protein kinase. 
Endocrinology. 1999;140:1525-1536 
109. Shaywitz AJ, Greenberg ME. Creb: A stimulus-induced transcription factor 
activated by a diverse array of extracellular signals. Annual review of 
biochemistry. 1999;68:821-861 
110. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C. Nf-kappab 
participates in the corticotropin-releasing, hormone-induced regulation of the 
pituitary proopiomelanocortin gene. The Journal of biological chemistry. 
2004;279:10837-10840 
111. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM, 
Latchman DS. Urocortin protects against ischemic and reperfusion injury via a 
mapk-dependent pathway. The Journal of biological chemistry. 2000;275:8508-
8514 
112. Markovic D, Punn A, Lehnert H, Grammatopoulos DK. Molecular determinants 
and feedback circuits regulating type 2 crh receptor signal integration. 
Biochimica et biophysica acta. 2011;1813:896-907 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 84  
 
113. Nemoto T, Mano-Otagiri A, Shibasaki T. Urocortin 2 induces tyrosine 
hydroxylase phosphorylation in pc12 cells. Biochemical and biophysical 
research communications. 2005;330:821-831 
114. Calderon-Sanchez E, Delgado C, Ruiz-Hurtado G, Dominguez-Rodriguez A, 
Cachofeiro V, Rodriguez-Moyano M, Gomez AM, Ordonez A, Smani T. Urocortin 
induces positive inotropic effect in rat heart. Cardiovascular research. 
2009;83:717-725 
115. Van Kolen K, Dautzenberg FM, Verstraeten K, Royaux I, De Hoogt R, Gutknecht 
E, Peeters PJ. Corticotropin releasing factor-induced erk phosphorylation in 
att20 cells occurs via a camp-dependent mechanism requiring epac2. 
Neuropharmacology. 2010;58:135-144 
116. Brar BK, Stephanou A, Knight R, Latchman DS. Activation of protein kinase b/akt 
by urocortin is essential for its ability to protect cardiac cells against 
hypoxia/reoxygenation-induced cell death. Journal of molecular and cellular 
cardiology. 2002;34:483-492 
117. Walther S, Pluteanu F, Renz S, Nikonova Y, Maxwell JT, Yang LZ, Schmidt K, 
Edwards JN, Wakula P, Groschner K, Maier LS, Spiess J, Blatter LA, Pieske B, 
Kockskamper J. Urocortin 2 stimulates nitric oxide production in ventricular 
myoctytes via akt- and pka-mediated phosphorylation of enos at serine 1177. 
American journal of physiology. Heart and circulatory physiology. 2014 
118. Chen Y, Zhao J, Du J, Xu G, Tang C, Geng B. Hydrogen sulfide regulates cardiac 
sarcoplasmic reticulum ca(2+) uptake via k(atp) channel and pi3k/akt pathway. 
Life sciences. 2012;91:271-278 
119. Yang LZ, Kockskamper J, Khan S, Suarez J, Walther S, Doleschal B, Unterer G, 
Khafaga M, Machler H, Heinzel FR, Dillmann WH, Pieske B, Spiess J. Camp- and 
ca(2)(+) /calmodulin-dependent protein kinases mediate inotropic, lusitropic 
and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes. 
British journal of pharmacology. 2011;162:544-556 
120. Grossini E, Molinari C, Mary DA, Uberti F, Ribichini F, Caimmi PP, Vacca G. 
Urocortin ii induces nitric oxide production through camp and ca2+ related 
pathways in endothelial cells. Cellular physiology and biochemistry : 
international journal of experimental cellular physiology, biochemistry, and 
pharmacology. 2009;23:87-96 
121. Grossini E, Caimmi PP, Molinari C, Mary DA, Uberti F, Vacca G. Modulation of 
calcium movements by urocortin ii in endothelial cells. Cellular physiology and 
biochemistry : international journal of experimental cellular physiology, 
biochemistry, and pharmacology. 2010;25:221-232 
122. Cantarella G, Lempereur L, Lombardo G, Chiarenza A, Pafumi C, Zappala G, 
Bernardini R. Divergent effects of corticotropin releasing hormone on 
endothelial cell nitric oxide synthase are associated with different expression of 
crh type 1 and 2 receptors. British journal of pharmacology. 2001;134:837-844 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 85  
 
123. Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, Nakao K, Kawamura 
M. Effects of urocortin ii on neonatal rat cardiac myocytes and non-myocytes. 
Peptides. 2005;26:2473-2481 
124. Kageyama K, Suda T. Urocortin-related peptides increase interleukin-6 output 
via cyclic adenosine 5'-monophosphate-dependent pathways in a7r5 aortic 
smooth muscle cells. Endocrinology. 2003;144:2234-2241 
125. Huang M, Kempuraj D, Papadopoulou N, Kourelis T, Donelan J, Manola A, 
Theoharides TC. Urocortin induces interleukin-6 release from rat 
cardiomyocytes through p38 map kinase, erk and nf-kappab activation. Journal 
of molecular endocrinology. 2009;42:397-405 
126. Walther S, Awad S, Lonchyna VA, Blatter LA. Nfat transcription factor regulation 
by urocortin ii in cardiac myocytes and heart failure. American journal of 
physiology. Heart and circulatory physiology. 2014;306:H856-866 
127. Venkatasubramanian S, Newby DE, Lang NN. Urocortins in heart failure. 
Biochem Pharmacol. 2010;80:289-296 
128. Yang LZ, Kockskamper J, Heinzel FR, Hauber M, Walther S, Spiess J, Pieske B. 
Urocortin ii enhances contractility in rabbit ventricular myocytes via crf(2) 
receptor-mediated stimulation of protein kinase a. Cardiovascular research. 
2006;69:402-411 
129. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, 
Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin ii: 
Acute effects in murine heart failure. Proceedings of the National Academy of 
Sciences of the United States of America. 2004;101:3697-3702 
130. Meili-Butz S, Buhler K, John D, Buser P, Vale WW, Peterson KL, Brink M, Dieterle 
T. Acute effects of urocortin 2 on cardiac function and propensity for 
arrhythmias in an animal model of hypertension-induced left ventricular 
hypertrophy and heart failure. European journal of heart failure. 2010;12:797-
804 
131. Liu CN, Yang C, Liu XY, Li S. In vivo protective effects of urocortin on ischemia-
reperfusion injury in rat heart via free radical mechanisms. Canadian journal of 
physiology and pharmacology. 2005;83:459-465 
132. Tao J, Xu H, Yang C, Liu CN, Li S. Effect of urocortin on l-type calcium currents in 
adult rat ventricular myocytes. Pharmacological research : the official journal of 
the Italian Pharmacological Society. 2004;50:471-476 
133. Charles CJ, Jardine DL, Rademaker MT, Richards AM. Urocortin 2 induces 
potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex 
activation in conscious sheep. The Journal of endocrinology. 2010;204:181-189 
134. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, Ferrari R, 
Knight R, Latchman DS. Urocortin promotes hemodynamic and bioenergetic 
recovery and improves cell survival in the isolated rat heart exposed to 
ischemia/reperfusion. J Am Coll Cardiol. 2002;40:155-161 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 86  
 
135. Dieterle T, Meili-Butz S, Buhler K, Morandi C, John D, Buser PT, Rivier J, Vale 
WW, Peterson KL, Brink M. Immediate and sustained blood pressure lowering 
by urocortin 2: A novel approach to antihypertensive therapy? Hypertension. 
2009;53:739-744 
136. Kageyama K, Furukawa K, Miki I, Terui K, Motomura S, Suda T. Vasodilative 
effects of urocortin ii via protein kinase a and a mitogen-activated protein 
kinase in rat thoracic aorta. Journal of cardiovascular pharmacology. 
2003;42:561-565 
137. Chen CY, Doong ML, Rivier JE, Tache Y. Intravenous urocortin ii decreases blood 
pressure through crf(2) receptor in rats. Regul Pept. 2003;113:125-130 
138. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW. Urocortin-induced relaxation 
in the human internal mammary artery. Cardiovascular research. 2005;65:913-
920 
139. Huang Y, Chan FL, Lau CW, Tsang SY, He GW, Chen ZY, Yao X. Urocortin-induced 
endothelium-dependent relaxation of rat coronary artery: Role of nitric oxide 
and k+ channels. British journal of pharmacology. 2002;135:1467-1476 
140. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, Lee 
KF. Corticotropin-releasing factor receptor 2 is a tonic suppressor of 
vascularization. Proceedings of the National Academy of Sciences of the United 
States of America. 2002;99:7734-7739 
141. Emeto TI, Moxon JV, Biros E, Rush CM, Clancy P, Woodward L, Moran CS, Jose 
RJ, Nguyen T, Walker PJ, Golledge J. Urocortin 2 is associated with abdominal 
aortic aneurysm and mediates anti-proliferative effects on vascular smooth 
muscle cells via corticotrophin releasing factor receptor 2. Clin Sci (Lond). 
2014;126:517-527 
142. Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M, Hirata K, 
Kawashima S, Yokozaki H, Yokoyama M. Endothelial urocortin has potent 
antioxidative properties and is upregulated by inflammatory cytokines and 
pitavastatin. Journal of vascular research. 2006;43:131-138 
143. Rademaker MT, Charles CJ, Ellmers LJ, Lewis LK, Nicholls MG, Richards AM. 
Prolonged urocortin 2 administration in experimental heart failure: Sustained 
hemodynamic, endocrine, and renal effects. Hypertension. 2011;57:1136-1144 
144. Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 inhibits 
furosemide-induced activation of renin and enhances renal function and 
diuretic responsiveness in experimental heart failure. Circulation. Heart failure. 
2009;2:532-540 
145. Brar BK, Stephanou A, Okosi A, Lawrence KM, Knight RA, Marber MS, Latchman 
DS. Crh-like peptides protect cardiac myocytes from lethal ischaemic injury. 
Molecular and cellular endocrinology. 1999;158:55-63 
146. Chen J, Tao J, Zhang R, Xu Y, Soong T, Li S. Urocortin inhibits mesenteric arterial 
remodeling in spontaneously hypertensive rats. Peptides. 2009;30:1117-1123 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 87  
 
147. Topal E, Yagmur J, Otlu B, Atas H, Cansel M, Acikgoz N, Ermis N. Relationship of 
urocortin-2 with systolic and diastolic functions and coronary artery disease: An 
observational study. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of 
cardiology. 2012;12:115-120 
148. Venkatasubramanian S, Griffiths ME, McLean SG, Miller MR, Luo R, Lang NN, 
Newby DE. Vascular effects of urocortins 2 and 3 in healthy volunteers. Journal 
of the American Heart Association. 2013;2:e004267 
149. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, 
Rademaker MT, Richards M. Urocortin 2 infusion in human heart failure. Eur 
Heart J. 2007;28:2589-2597 
150. Smani T, Calderon E, Rodriguez-Moyano M, Dominguez-Rodriguez A, Diaz I, 
Ordonez A. Urocortin-2 induces vasorelaxation of coronary arteries isolated 
from patients with heart failure. Clinical and experimental pharmacology & 
physiology. 2011;38:71-76 
151. Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM. 
Plasma urocortin 1 in human heart failure. Circulation. Heart failure. 
2009;2:465-471 
152. Dautzenberg FM, Hauger RL. The crf peptide family and their receptors: Yet 
more partners discovered. Trends in pharmacological sciences. 2002;23:71-77 
153. Breu J, Touma C, Holter SM, Knapman A, Wurst W, Deussing JM. Urocortin 2 
modulates aspects of social behaviour in mice. Behav Brain Res. 2012;233:331-
336 
154. Fekete EM, Zhao Y, Szucs A, Sabino V, Cottone P, Rivier J, Vale WW, Koob GF, 
Zorrilla EP. Systemic urocortin 2, but not urocortin 1 or stressin 1-a, suppresses 
feeding via crf2 receptors without malaise and stress. British journal of 
pharmacology. 2011;164:1959-1975 
155. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human 
studies revisited. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology. 2008;22:659-661 
156. Lourenco AP, Vasques-Novoa F, Oliveira-Pinto J, Fontoura D, Roncon-
Albuquerque R, Jr., Leite-Moreira AF. Haemodynamic and neuroendocrine 
effects of tezosentan in chronic experimental pulmonary hypertension. 
Intensive care medicine. 2012;38:1050-1060 
157. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial 
hypertension for clinicians: New concepts and experimental therapies. 
Circulation. 2010;121:2045-2066 
158. Lourenco AP, Vasques-Novoa F, Fontoura D, Bras-Silva C, Roncon-Albuquerque 
R, Jr., Leite-Moreira AF. A western-type diet attenuates pulmonary 
hypertension with heart failure and cardiac cachexia in rats. The Journal of 
nutrition. 2011;141:1954-1960 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 88  
 
159. Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML, Lakatta EG. Use of tibial length 
to quantify cardiac hypertrophy: Application in the aging rat. The American 
journal of physiology. 1982;243:H941-947 
160. Bupha-Intr T, Haizlip KM, Janssen PM. Role of endothelin in the induction of 
cardiac hypertrophy in vitro. PloS one. 2012;7:e43179 
161. Booth J, Pinney J, Davenport A. N-terminal probnp--marker of cardiac 
dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clinical 
journal of the American Society of Nephrology : CJASN. 2010;5:1036-1040 
162. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. 
Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression 
of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll 
Cardiol. 2005;46:2116-2124 
163. Roux PP, Blenis J. Erk and p38 mapk-activated protein kinases: A family of 
protein kinases with diverse biological functions. Microbiology and molecular 
biology reviews : MMBR. 2004;68:320-344 
164. Burgering BM, Coffer PJ. Protein kinase b (c-akt) in phosphatidylinositol-3-oh 
kinase signal transduction. Nature. 1995;376:599-602 
165. Heim MH. The jak-stat pathway: Cytokine signalling from the receptor to the 
nucleus. Journal of receptor and signal transduction research. 1999;19:75-120 
166. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, Zhang YY. Serial noninvasive 
assessment of progressive pulmonary hypertension in a rat model. American 
journal of physiology. Heart and circulatory physiology. 2002;283:H364-371 
167. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-
resolution echocardiography and magnetic resonance imaging vs. High-fidelity 
catheterization in experimental pulmonary hypertension. American journal of 
physiology. Lung cellular and molecular physiology. 2010;299:L401-412 
168. Koskenvuo JW, Mirsky R, Zhang Y, Angeli FS, Jahn S, Alastalo TP, Schiller NB, 
Boyle AJ, Chatterjee K, De Marco T, Yeghiazarians Y. A comparison of 
echocardiography to invasive measurement in the evaluation of pulmonary 
arterial hypertension in a rat model. The international journal of cardiovascular 
imaging. 2010;26:509-518 
169. Naeije RaH, S. Right ventricular function in pulmonary hypertension: 
Physiological concepts. European Heart Journal Supplements 9(H). 2007;H5-H9 
170. Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel MC, Tan HL. Sequence 
of echocardiographic changes during development of right ventricular failure in 
rat. Journal of the American Society of Echocardiography : official publication of 
the American Society of Echocardiography. 2006;19:1272-1279 
171. Chen L, Gan XT, Haist JV, Feng Q, Lu X, Chakrabarti S, Karmazyn M. Attenuation 
of compensatory right ventricular hypertrophy and heart failure following 
monocrotaline-induced pulmonary vascular injury by the na+-h+ exchange 
inhibitor cariporide. J Pharmacol Exp Ther. 2001;298:469-476 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 89  
 
172. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, 
Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail 
DB. Right ventricular function and failure: Report of a national heart, lung, and 
blood institute working group on cellular and molecular mechanisms of right 
heart failure. Circulation. 2006;114:1883-1891 
173. Yamamoto S. Single lung transplantation for the treatment of monocrotaline-
induced pulmonary hypertension in the rat. Acta medica Nagasakiensia 40. 
1995;(1-4):38-43 
174. Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models 
to evaluate treatments for pulmonary hypertension? Naunyn-Schmiedeberg's 
archives of pharmacology. 2006;373:391-400 
175. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, 
Latchman DS, Lee KF, Vale W. Urocortin-ii and urocortin-iii are cardioprotective 
against ischemia reperfusion injury: An essential endogenous cardioprotective 
role for corticotropin releasing factor receptor type 2 in the murine heart. 
Endocrinology. 2004;145:24-35; discussion 21-23 
176. Phrommintikul A, Sivasinprasasn S, Lailerd N, Chattipakorn S, Kuanprasert S, 
Chattipakorn N. Plasma urocortin in acute myocardial infarction patients. 
European journal of clinical investigation. 2010;40:874-882 
177. Haworth SG. The cell and molecular biology of right ventricular dysfunction in 
pulmonary hypertension. European Heart Journal Supplements 9(H). 2007:H10-
H16 
178. Charles CJ, Rademaker MT, Richards AM. Urocortin 1 modulates the 
neurohumoral response to acute nitroprusside-induced hypotension in sheep. 
Clin Sci (Lond). 2007;112:485-491 
179. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 
in pulmonary hypertension: Marker or mediator of disease? Annals of internal 
medicine. 1991;114:464-469 
180. Ichikawa KI, Hidai C, Okuda C, Kimata SI, Matsuoka R, Hosoda S, Quertermous 
T, Kawana M. Endogenous endothelin-1 mediates cardiac hypertrophy and 
switching of myosin heavy chain gene expression in rat ventricular 
myocardium. J Am Coll Cardiol. 1996;27:1286-1291 
181. Lourenco AP, Roncon-Albuquerque R, Jr., Bras-Silva C, Faria B, Wieland J, 
Henriques-Coelho T, Correia-Pinto J, Leite-Moreira AF. Myocardial dysfunction 
and neurohumoral activation without remodeling in left ventricle of 
monocrotaline-induced pulmonary hypertensive rats. American journal of 
physiology. Heart and circulatory physiology. 2006;291:H1587-1594 
182. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe 
T, Schwaiblmair M, Behr J. Clinical significance of brain natriuretic peptide in 
primary pulmonary hypertension. J Am Coll Cardiol. 2004;43:764-770 
183. King L, Wilkins MR. Natriuretic peptide receptors and the heart. Heart. 
2002;87:314-315 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 90  
 
184. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, Kuribayashi S, 
Hamada S, Kakishita M, Nakanishi N, Takamiya M, Kunieda T, Matsuo H, 
Kangawa K. Plasma brain natriuretic peptide levels increase in proportion to the 
extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll 
Cardiol. 1998;31:202-208 
185. Chu W, Wan L, Zhao D, Qu X, Cai F, Huo R, Wang N, Zhu J, Zhang C, Zheng F, Cai 
R, Dong D, Lu Y, Yang B. Mild hypoxia-induced cardiomyocyte hypertrophy via 
up-regulation of hif-1alpha-mediated trpc signalling. Journal of cellular and 
molecular medicine. 2012;16:2022-2034 
186. Zhou YF, Zheng XW, Zhang GH, Zong ZH, Qi GX. The effect of hypoxia-inducible 
factor 1-alpha on hypoxia-induced apoptosis in primary neonatal rat ventricular 
myocytes. Cardiovascular journal of Africa. 2010;21:37-41 
187. Buhler K, Plaisance I, Dieterle T, Brink M. The human urocortin 2 gene is 
regulated by hypoxia: Identification of a hypoxia-responsive element in the 3'-
flanking region. The Biochemical journal. 2009;424:119-127 
188. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. 
Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320-323 
189. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, de Rienzo A, 
Roncarati R, Trimarco B, Lembo G. Increased cardiomyocyte apoptosis and 
changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left 
ventricular adaptations to chronic pressure overload in the rat. Circulation. 
1999;99:3071-3078 
190. Gao XF, Zhou Y, Wang DY, Lew KS, Richards AM, Wang P. Urocortin-2 
suppression of p38-mapk signaling as an additional mechanism for ischemic 
cardioprotection. Molecular and cellular biochemistry. 2014 
191. Tao J, Zhang Y, Soong TW, Li S. Urocortin ii inhibits the apoptosis of mesenteric 
arterial smooth muscle cells via l-type calcium channels in spontaneously 
hypertensive rats. Cellular physiology and biochemistry : international journal 
of experimental cellular physiology, biochemistry, and pharmacology. 
2006;17:111-120 
192. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD, Dal Bello B, 
Semigran MJ, Bielsa-Masdeu A, Dec GW, Israels S, Ballester M, Virmani R, 
Saxena S, Kharbanda S. Apoptosis in heart failure: Release of cytochrome c 
from mitochondria and activation of caspase-3 in human cardiomyopathy. 
Proceedings of the National Academy of Sciences of the United States of 
America. 1999;96:8144-8149 
193. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis 
in mouse myocardium: Mitochondrial cytochrome c-mediated caspase-3 
activation pathway. Diabetes. 2002;51:1938-1948 
194. Yen CH, Tsai TH, Leu S, Chen YL, Chang LT, Chai HT, Chung SY, Chua S, Tsai CY, 
Chang HW, Ko SF, Sun CK, Yip HK. Sildenafil improves long-term effect of 
endothelial progenitor cell-based treatment for monocrotaline-induced rat 
pulmonary arterial hypertension. Cytotherapy. 2013;15:209-223 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 91  
 
195. Lee FY, Lu HI, Zhen YY, Leu S, Chen YL, Tsai TH, Chung SY, Chua S, Sheu JJ, Hsu 
SY, Chang HW, Sun CK, Yip HK. Benefit of combined therapy with nicorandil and 
colchicine in preventing monocrotaline-induced rat pulmonary arterial 
hypertension. European journal of pharmaceutical sciences : official journal of 
the European Federation for Pharmaceutical Sciences. 2013;50:372-384 
196. Condorelli G, Roncarati R, Ross J, Jr., Pisani A, Stassi G, Todaro M, Trocha S, 
Drusco A, Gu Y, Russo MA, Frati G, Jones SP, Lefer DJ, Napoli C, Croce CM. 
Heart-targeted overexpression of caspase3 in mice increases infarct size and 
depresses cardiac function. Proceedings of the National Academy of Sciences of 
the United States of America. 2001;98:9977-9982 
197. Fan Q, Huang ZM, Boucher M, Shang X, Zuo L, Brinks H, Lau WB, Zhang J, 
Chuprun JK, Gao E. Inhibition of fas-associated death domain-containing 
protein (fadd) protects against myocardial ischemia/reperfusion injury in a 
heart failure mouse model. PloS one. 2013;8:e73537 
198. Hsieh YP, Huang CH, Lee CY, Lin CY, Chang CC. Silencing of hepcidin enforces 
the apoptosis in iron-induced human cardiomyocytes. J Occup Med Toxicol. 
2014;9:11 
199. Yuan Z, McCauley R, Chen-Scarabelli C, Abounit K, Stephanou A, Barry SP, 
Knight R, Saravolatz SF, Saravolatz LD, Ulgen BO, Scarabelli GM, Faggian G, 
Mazzucco A, Saravolatz L, Scarabelli TM. Activation of src protein tyrosine 
kinase plays an essential role in urocortin-mediated cardioprotection. 
Molecular and cellular endocrinology. 2010;325:1-7 
200. Chen QM, Tu VC, Purdon S, Wood J, Dilley T. Molecular mechanisms of cardiac 
hypertrophy induced by toxicants. Cardiovascular toxicology. 2001;1:267-283 
201. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. The 
mode of bone morphogenetic protein (bmp) receptor oligomerization 
determines different bmp-2 signaling pathways. The Journal of biological 
chemistry. 2002;277:5330-5338 
202. Kiss T, Kovacs K, Komocsi A, Tornyos A, Zalan P, Sumegi B, Gallyas F, Jr. Novel 
mechanisms of sildenafil in pulmonary hypertension involving 
cytokines/chemokines, map kinases and akt. PloS one. 2014;9:e104890 
203. Kehat I, Molkentin JD. Extracellular signal-regulated kinase 1/2 (erk1/2) 
signaling in cardiac hypertrophy. Annals of the New York Academy of Sciences. 
2010;1188:96-102 
204. Bartelds B, Borgdorff MA, Smit-van Oosten A, Takens J, Boersma B, Nederhoff 
MG, Elzenga NJ, van Gilst WH, De Windt LJ, Berger RM. Differential responses 
of the right ventricle to abnormal loading conditions in mice: Pressure vs. 
Volume load. European journal of heart failure. 2011;13:1275-1282 
205. Li XM, Ma YT, Yang YN, Liu F, Chen BD, Han W, Zhang JF, Gao XM. 
Downregulation of survival signalling pathways and increased apoptosis in the 
transition of pressure overload-induced cardiac hypertrophy to heart failure. 
Clinical and experimental pharmacology & physiology. 2009;36:1054-1061 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
References| 92  
 
206. Perez Lopez I, Cariolato L, Maric D, Gillet L, Abriel H, Diviani D. A-kinase 
anchoring protein lbc coordinates a p38 activating signaling complex controlling 
compensatory cardiac hypertrophy. Molecular and cellular biology. 
2013;33:2903-2917 
207. Mosele F, Tavares AM, Colombo R, Caron-Lienert R, Araujo AS, Ribeiro MF, 
Bello-Klein A. Effects of purple grape juice in the redox-sensitive modulation of 
right ventricular remodeling in a pulmonary arterial hypertension model. 
Journal of cardiovascular pharmacology. 2012;60:15-22 
208. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, 
Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R. 
Constitutive activation of stat3 signaling confers resistance to apoptosis in 
human u266 myeloma cells. Immunity. 1999;10:105-115 
209. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, 
Cote J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators 
of transcription-3/pim1 axis plays a critical role in the pathogenesis of human 
pulmonary arterial hypertension. Circulation. 2011;123:1205-1215 
210. Chen-Scarabelli C, Saravolatz Ii L, McCaukey R, Scarabelli G, Di Rezze J, Mohanty 
B, Barry S, Latchman D, Georgiadis V, McCormick J, Saravolatz L, Knight R, 
Faggian G, Narula J, Stephanou A, Scarabelli TM. The cardioprotective effects of 
urocortin are mediated via activation of the src tyrosine kinase-stat3 pathway. 
Jak-Stat. 2013;2:e24812 
 
  
 
 
 
 
 
 
APPENDIX 
 
 
 
 
 
 
 
 
 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Appendix| 94  
 
Publications as Full Texts: 
Santos-Ribeiro D*, Adão R*, Rademaker M, Leite-Moreira AF, Brás-Silva C. Urocortin-2 in 
Cardiovascular Health and Disease. Drug Discovery Today, 2014 (in revision). 
Mendes-Ferreira P, Adão R, Maia-Rocha C, Alves BS, Santos-Ribeiro D, Lourenço AP, Mendes 
MJ, Cerqueira RJ, Castro-Chaves P, De Keulenaer GW, Leite-Moreira AF, Brás-Silva C. 
Neuregulin-1 improves right ventricular function and attenuates monocrotaline-induced 
pulmonary arterial hypertension. Cardiovascular Research, 2014 (submitted). 
 
Publications as Abstracts: 
Santos-Ribeiro D, Mendes-Ferreira P, Alves BS, Adão R, Maia-Rocha C, Leite-Moreira AF, Brás-
Silva C. Molecular mechanisms underlying the beneficial effects of neuregulin-1 in the 
treatment of pulmonary arterial hypertension. 7th Meeting of Young Researchers of University 
of Porto 2014, Book of abstracts, page 54. 
Alves BS, Santos-Ribeiro D, Adão R, Maia-Rocha C, Mendes-Ferreira P, Leite-Moreira AF, Brás-
Silva C. Modulation of right ventricle function by neuregulin-1 – therapeutic implications in 
pulmonary hypertension. 7th Meeting of Young Researchers of University of Porto 2014, Book 
of abstracts, page 56. 
Mendes-Ferreira P, Santos-Ribeiro D, Alves BS, Adão R, Maia-Rocha C, Leite-Moreira AF, De 
Keulenaer GW, Brás-Silva C. Reversão da hipertrofia ventricular direita pela neuregulina-1. 
Revista Portuguesa de Cardiologia 2014, vol. 33 (Especial congresso): 69-70. 
Adão R, Mendes-Ferreira P, Maia-Rocha C, Alves BS, Santos-Ribeiro D, Falcão-Pires I, De 
Keulenaer GW, Leite-Moreira AF, Brás-Silva C. A neuregulina-1 modula a função dos 
cardiomiócitos do ventrículo direito na hipertensão arterial pulmonar. Revista Portuguesa de 
Cardiologia 2014, vol. 33 (Especial congresso): 164. 
Maia-Rocha C, Mendes-Ferreira P, Adão R, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Mecanismos moleculares subjacentes aos efeitos benéficos da 
neuregulina-1 no tratamento da hipertensão arterial pulmonar. Revista Portuguesa de 
Cardiologia 2014, vol. 33 (Especial congresso): 69. 
Mendes-Ferreira P, Santos-Ribeiro D, Alves BS, Adão R, Maia-Rocha C, Leite-Moreira AF, De 
Keulenaer GW, Brás-Silva C. Neuregulin-1 attenuates right ventricle hypertrophy in a model of 
pulmonary artery banding. European Journal of Heart Failure 2014, 16 S2:112. 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Appendix| 95  
 
Maia-Rocha C, Mendes-Ferreira P, Adão R, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Molecular mechanisms underlying the beneficial effects of 
neuregulin-1 in pulmonary arterial hypertension. Cardiovascular Research 2014, 103 S1:138. 
Maia-Rocha C, Mendes-Ferreira P, Adão R, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. The right ventricle molecular changes associated with 
pulmonary arterial hypertension are attenuated by neuregulin-1 treatment. European Heart 
Journal 2014, 35:1046. 
Santos-Ribeiro D, Adão R, Maia-Rocha C, Alves BS, Mendes-Ferreira P, Leite-Moreira AF, Brás-
Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial hypertension. 
Circulation 2014 (in press). 
Santos-Ribeiro D, Alves BS, Adão R, Maia-Rocha C, Mendes-Ferreira P, Leite-Moreira AF, Brás-
Silva C. Urocortin-2 improves right ventricular function in pulmonar arterial hypertension. 
Young European Scientist Meeting 2014 Abstract Book, page 61. 
Alves BS, Santos-Ribeiro D, Adão R, Maia-Rocha C, Mendes-Ferreira P, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Right ventricle pressure overload-induced hypertrophy is 
attenuated by neuregulin-1. Young European Scientist Meeting 2014 Abstract Book, page 62. 
Maia-Rocha C, Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Molecular mechanisms underlying the beneficial effects of 
neuregulin-1 in pulmonary arterial hypertension. Young European Scientist Meeting 2014 
Abstract Book, page 63. 
Adão R, Alves BS, Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, Hamdani N, Mendes 
MJ, Falcão-Pires I, De Keulenaer GW, Linke W, Leite-Moreira AF, Brás-Silva C. Neuregulin-1 
preserves right ventricular diastolic function in animal model of pulmonary arterial 
hypertension. Young European Scientist Meeting 2014 Abstract Book, page 50. 
Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Maia-Rocha C, Alves BS, Leite-Moreira AF, Brás-
Silva C. Urocortin-2 improves right ventricular function in pulmonar arterial hypertension. 
Heart Without Borders – Cardiovascular Development, Disease and Repair – International 
Conference 2014. Abstract Book, page 91. 
Mendes-Ferreira P, Adão R, Maia-Rocha C, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Neuregulin-1 improves right ventricular function and attenuates 
monocrotaline-induced pulmonary arterial hypertension. Heart Without Borders – 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Appendix| 96  
 
Cardiovascular Development, Disease and Repair – International Conference 2014. Abstract 
Book, page 90. 
Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Maia-Rocha C, Alves BS, Rademaker M, Leite-
Moreira AF, Brás-Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial 
hypertension. European Journal of Heart Failure 2015 (accepted). 
 
Communications at Scientific Meetings 
Oral Communications 
Santos-Ribeiro D, Mendes-Ferreira P, Alves BS, Adão R, Maia-Rocha C, Leite-Moreira AF, Brás-
Silva C. Molecular mechanisms underlying the beneficial effects of neuregulin-1 in the 
treatment of pulmonary arterial hypertension. 7th Meeting of Young Researchers of University 
of Porto (IJUP) 2014 February. Oporto, Portugal. 
Alves BS, Santos-Ribeiro D, Adão R, Maia-Rocha C, Mendes-Ferreira P, Leite-Moreira AF, Brás-
Silva C. Modulation of right ventricle function by neuregulin-1 – therapeutic implications in 
pulmonary hypertension. 7th Meeting of Young Researchers of University of Porto (IJUP) 2014 
February. Oporto, Portugal. 
Mendes-Ferreira P, Santos-Ribeiro D, Alves BS, Adão R, Maia-Rocha C, Leite-Moreira AF, De 
Keulenaer GW, Brás-Silva C. Neuregulin-1 attenuates right ventricle hypertrophy in a model of 
pulmonary artery banding. Heart Failure 2014 May. Athens, Greece. 
Adão R, Alves BS, Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, Hamdani N, Mendes 
MJ, Falcão-Pires I, De Keulenaer GW, Linke W, Leite-Moreira AF, Brás-Silva C. Neuregulin-1 
preserves right ventricular diastolic function in animal model of pulmonary arterial 
hypertension. 9th Young European Scientist Meeting 2014 September. Oporto, Portugal. 
 
Poster Communications 
2013 
Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, Adão R, Leite-Moreira AF, Brás-Silva C. 
The role of miRNA-146a in pulmonary arterial hypertension. Fundação Astrazeneca Innovate 
Competition – 5.0 iMed Conference 2013 October. Lisbon, Portugal. 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Appendix| 97  
 
Adão R, Mendes-Ferreira P, Maia-Rocha C, Santos-Ribeiro D, Rademaker M, Leite-Moreira AF, 
Brás-Silva C. UCN-2/CRHR2 system role in pulmonary hypertension – pathophysiological and 
therapeutic implications. Fundação Astrazeneca Innovate Competition – 5.0 iMed Conference 
2013 October. Lisbon, Portugal. 
2014 
Mendes-Ferreira P, Santos-Ribeiro D, Alves BS, Adão R, Maia-Rocha C, Leite-Moreira AF, De 
Keulenaer GW, Brás-Silva C. Reversão da hipertrofia ventricular direita pela neuregulina-1. 
XXXV Congresso Português de Cardiologia 2014 Abril. Albufeira, Portugal. 
Maia-Rocha C, Adão R, Mendes-Ferreira P, Santos-Ribeiro D, Alves BS, Leite-Moreira AF, De 
Keulenaer GW, Brás-Silva C. Mecanismos moleculares associados aos efeitos benéficos da 
neuregulina-1 no tratamento da hipertensão arterial pulmonar. XXXV Congresso Português de 
Cardiologia 2014 Abril. Albufeira, Portugal. 
Adão R, Mendes-Ferreira P, Maia-Rocha C, Alves BS, Santos-Ribeiro D, Falcão-Pires I, De 
Keulenaer GW, Leite-Moreira AF, Brás-Silva C. a neuregulina-1 modula a função dos 
cardiomiócitos do ventrículo direito na hipertensão arterial pulmonar. XXXV Congresso 
Português de Cardiologia 2014 Abril. Albufeira, Portugal. 
Maia-Rocha C, Mendes-Ferreira P, Adão R, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Molecular mechanisms underlying the beneficial effects of 
neuregulin-1 in pulmonary arterial hypertension. Frontiers in Cardiovascular Biology 2014 July. 
Barcelona, Spain. 
Maia-Rocha C, Mendes-Ferreira P, Adão R, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. the right ventricle molecular changes associated with pulmonar 
arterial hypertension are attenuated by neuregulin-1 treatment. European Society of 
Cardiology Congress 2014 August/September. Barcelona, Spain. 
Santos-Ribeiro D, Alves BS, Adão R, Maia-Rocha C, Mendes-Ferreira P, Leite-Moreira AF, Brás-
Silva C. Urocortin-2 improves right ventricular function in pulmonar arterial hypertension. 9th 
Young European Scientist Meeting 2014 September. Oporto, Portugal. 
Alves BS, Santos-Ribeiro D, Adão R, Maia-Rocha C, Mendes-Ferreira P, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Right ventricle pressure overload-induced hypertrophy is 
attenuated by neuregulin-1. 9th Young European Scientist Meeting 2014 September. Oporto, 
Portugal. 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Appendix| 98  
 
Maia-Rocha C, Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Molecular mechanisms underlying the beneficial effects of 
neuregulin-1 in pulmonary arterial hypertension. 9th Young European Scientist Meeting 2014 
September. Oporto, Portugal. 
Santos-Ribeiro D, Adão R, Maia-Rocha C, Alves BS, Mendes-Ferreira P, Leite-Moreira AF, Brás-
Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial hypertension. 
American Heart Association Scientific Sessions 2014 November. Chicago, USA. 
Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Maia-Rocha C, Alves BS, Leite-Moreira AF, Brás-
Silva C. Urocortin-2 improves right ventricular function in pulmonar arterial hypertension. 
Heart Without Borders – Cardiovascular Development, Disease and Repair – International 
Conference 2014 November. Porto, Portugal. 
Mendes-Ferreira P, Adão R, Maia-Rocha C, Santos-Ribeiro D, Alves BS, De Keulenaer GW, 
Leite-Moreira AF, Brás-Silva C. Neuregulin-1 improves right ventricular function and attenuates 
monocrotaline-induced pulmonary arterial hypertension. Heart Without Borders – 
Cardiovascular Development, Disease and Repair – International Conference 2014 November. 
Porto, Portugal. 
2015 
Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Maia-Rocha C, Alves BS, Rademaker M, Leite-
Moreira AF, Brás-Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial 
hypertension. Heart Failure Association Winter Research Meeting 2015 January. Les Diablerets, 
Switzerland (accepted). 
 
Research Projects 
Role of the neuregulin system in pulmonary arterial hypertension – pathophysiological and 
therapeutic implications. Carmen Brás Silva, Faculdade de Medicina da Universidade do Porto, 
PTDC/SAU-FCF/100442/2008. 
Pathophysiological role and therapeutic potential of urocortin-2 in pulmonary hypertension. 
Carmen Brás Silva, Faculdade de Medicina da Universidade do Porto, PTDC/DTP-
FTO/0130/2012. 
The role of miRNA-146a in pulmonary arterial hypertension. Pedro Ferreira, Diana Ribeiro, 
Carolina Rocha, Rui Adão, Bárbara Alves, Adelino Leite Moreira, Carmen Brás Silva, Faculdade 
The Role of Urocortin-2 in Pulmonary Arterial Hypertension 
Master Thesis on Molecular and Cellular Biology 
 
Appendix| 99  
 
de Medicina da Universidade do Porto, Bolsa de Estudo João Porto da Sociedade Portuguesa 
de Cardiologia 2013/2014. 
 
Research Prizes 
Bolsa de Estudo João Porto da Sociedade Portuguesa de Cardiologia 2013/2014 – Mendes-
Ferreira P, Santos-Ribeiro D, Maia-Rocha C, Adão R, Alves BS, Leite-Moreira AF, Brás-Silva C. O 
Papel do miRNA-146a na hipertensão arterial pulmonar. 
Prémio Servier de Investigação Básica da Sociedade Portuguesa de Cardiologia 2014 – Mendes-
Ferreira P, Maia-Rocha C, Adão R, Santos-Ribeiro D, Alves BS, Cerqueira RJ, Mendes MJ, Leite-
Moreira AF, Brás-Silva C. A neuregulina-1 reduz a hipertensão arterial pulmonar e a disfunção 
ventricular direita num modelo experimental de hipertensão pulmonar.  
Physiology & Immunology Poster Presentation First Prize, 9th Young European Scientist 
Meeting 2014 – Maia-Rocha C, Santos-Ribeiro D, Mendes-Ferreira P, Adão R, Alves BS, De 
Keulenaer GW, Leite-Moreira AF, Brás-Silva C. Molecular mechanisms underlying the beneficial 
effects of neuregulin-1 in pulmonary arterial hypertension. 
Physiology & Immunology Parallel Oral Session First Prize, 9th Young European Scientist 
Meeting 2014 – Adão R, Alves BS, Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, 
Hamdani N, Mendes MJ, Falcão-Pires I, De Keulenaer GW, Linke W, Leite-Moreira AF, Brás-Silva 
C. Neuregulin-1 preserves right ventricular diastolic function in animal model of pulmonary 
arterial hypertension. 
